var docs;if (!docs) docs =[]; docs["114"]={"11400":"<p><b>Title</b> CYP3A4 Substrates (High risk with Inhibitors) / Ivacaftor</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: No interaction is expected when tezacaftor/ivacaftor is combined with CYP3A4 substrates.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Ivacaftor may increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action is required for most CYP3A4 substrates. Consider increased monitoring for drugs with very narrow therapeutic indexes when combined with ivacaftor monotherapy. No action is required when tezacaftor/ivacaftor is combined with CYP3A4 substrates.</p>\n<div>\n <p><b>CYP3A4 Substrates (High risk with Inhibitors) Interacting Members</b> Abemaciclib, Acalabrutinib, Ado-Trastuzumab Emtansine, Alfentanil, Alfuzosin, Alitretinoin (Systemic), ALPRAZolam, Amiodarone, AmLODIPine, Aprepitant, ARIPiprazole, ARIPiprazole Lauroxil, Asunaprevir, Atazanavir, AtorvaSTATin, Avanafil, Axitinib, Barnidipine, Benidipine, Benzhydrocodone, Blonanserin, Bosutinib, Brexpiprazole, Brigatinib, Bromocriptine, Bromperidol, Budesonide (Systemic), Buprenorphine, BusPIRone, Cabazitaxel, Cabozantinib, Calcitriol (Systemic), CarBAMazepine, Cariprazine, Ceritinib, ChlordiazePOXIDE, Chloroquine, Cilnidipine, Cilostazol, Cinacalcet, Cisapride, Citalopram, Clarithromycin, ClonazePAM, Cobimetinib, Colchicine, Conivaptan, Copanlisib, Crizotinib, CycloSPORINE (Systemic), Cyproterone, Dabrafenib, Daclatasvir, Dapoxetine, Darifenacin, Darunavir, Dasatinib, Deflazacort, Dexamethasone (Systemic), DiazePAM, Digitoxin, Dihydroergotamine, DilTIAZem, Disopyramide, DOCEtaxel, Domperidone, Doxazosin, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Dronedarone, Dydrogesterone, Ebastine, Elbasvir, Eletriptan, Eliglustat, Eplerenone, Ergoloid Mesylates, Ergonovine, Ergotamine, Erlotinib, Erythromycin (Systemic), Escitalopram, Eszopiclone, Ethosuximide, Etizolam, Everolimus, Felbamate, Felodipine, FentaNYL, Fesoterodine, Flibanserin, Flurazepam, Fluticasone (Oral Inhalation), Fosaprepitant, Gefitinib, Grazoprevir, GuanFACINE, Halofantrine, Haloperidol, HYDROcodone, HYDROXYprogesterone Caproate, Ibrutinib, Irinotecan (Conventional), Irinotecan (Liposomal), Isavuconazonium Sulfate, Isosorbide Dinitrate, Isosorbide Mononitrate, Isradipine, Itraconazole, Ivabradine, Ivacaftor, Ixabepilone, Ketamine, Lacidipine, Lapatinib, Lercanidipine, Levomilnacipran, Lidocaine (Systemic), Lidocaine (Topical), Lomitapide, Lovastatin, Lurasidone, Macitentan, Manidipine, Maraviroc, Mefloquine, Methadone, Methylergonovine, Midazolam, Midostaurin, MiFEPRIStone, Mirodenafil, Mirtazapine, Naloxegol, Nefazodone, Neratinib, NiCARdipine, NIFEdipine, Nilotinib, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Olaparib, Olmutinib, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, OxyCODONE, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Pimavanserin, Pimozide, Piperaquine, Praziquantel, QUEtiapine, QuiNIDine, QuiNINE, Radotinib, Ranolazine, Reboxetine, Regorafenib, Ribociclib, Rupatadine, Ruxolitinib, Salmeterol, SAXagliptin, Sildenafil, Silodosin, Simeprevir, Simvastatin, Sirolimus, Solifenacin, Sonidegib, Stiripentol, SUFentanil, SUNItinib, Suvorexant, Tacrolimus (Systemic), Tadalafil, Tamoxifen, Tamsulosin, Telaprevir, Telithromycin, Temsirolimus, Teniposide, Tezacaftor, TiaGABine, Tofacitinib, Tolterodine, Tolvaptan, Trabectedin, TraZODone, Triazolam, Trimipramine, Udenafil, Valbenazine, Vardenafil, Vemurafenib, Venetoclax, Venlafaxine, Verapamil, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vinflunine, Vinorelbine, Zopiclone</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the ivacaftor prescribing information, ivacaftor increased the oral midazolam AUC and maximum serum concentration (Cmax) approximately 50% and 30%, respectively.<sup>1</sup> In contrast, when tezacaftor/ivacaftor (100 mg/150 mg daily every morning) and ivacaftor (150 mg daily every evening) were combined with midazolam (2 mg single oral dose) the midazolam AUC and Cmax only increased 12% and 13%, respectively.<sup>2</sup><br><br>Midazolam is considered a sensitive substrate for CYP3A4, often used in studies to detect CYP3A4 inhibition or induction. The results of this pharmacokinetic study suggest ivacaftor alone is a weak CYP3A4 inhibitor, while the combination of tezacaftor and ivacaftor is not a clinically relevant CYP3A4 inhibitor. This degree of inhibition is unlikely to be of clinical relevance for most CYP3A4 substrates.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kalydeco (ivacaftor) [prescribing information]. Boston, MA: Vertex Pharmaceuticals Inc; May 2017.</p>\n<p>2. Symdeko (tezacaftor and ivacaftor) [prescribing information]. Boston, MA: Vertex Pharmaceuticals Inc; February 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11401":"<p><b>Title</b> Neratinib / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Neratinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of neratinib and strong CYP3A4 inhibitors.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 22 healthy volunteers, the strong CYP3A4 inhibitor ketoconazole (400 mg once daily for 5 days) increased the neratinib (240 mg single dose given on day 2) AUC and maximum serum concentration 4.8-fold and 3.2-fold, respectively.<sup>1</sup><br><br>Neratinib prescribing information states that because strong CYP3A4 inhibitors can increase neratinib concentrations and lead to an increased risk of adverse effects, concomitant use of neratinib and strong CYP3A4 inhibitors should be avoided.<sup>2</sup><br><br>The mechanism of this interaction is likely ketoconazole-mediated inhibition of CYP3A4, an enzyme responsible for neratinib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D. Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects. <i>Br J Clin Pharmacol</i>. 2011;71(4):522-527. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21395644\">[PubMed 21395644]</a></p>\n<p>2. Nerlynx (neratinib) [prescribing information]. Los Angeles, CA: Puma Biotechnology Inc; July 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11402":"<p><b>Title</b> Neratinib / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Neratinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of neratinib and moderate CYP3A4 inhibitors.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> The use of moderate CYP3A4 inhibitors and neratinib has not been evaluated in a clinical study. However, in a pharmacokinetic study of 22 healthy volunteers, the strong CYP3A4 inhibitor ketoconazole (400 mg once daily for 5 days) increased the neratinib (240 mg single dose given on day 2) AUC and maximum serum concentration 4.8-fold and 3.2-fold, respectively.<sup>1</sup><br><br>Neratinib prescribing information states that because moderate CYP3A4 inhibitors may increase neratinib concentrations and lead to an increased risk of adverse effects, concomitant use of neratinib and moderate CYP3A4 inhibitors should be avoided.<sup>2</sup><br><br>The mechanism of this interaction is likely ketoconazole-mediated inhibition of CYP3A4, an enzyme responsible for neratinib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D. Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects. <i>Br J Clin Pharmacol</i>. 2011;71(4):522-527. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21395644\">[PubMed 21395644]</a></p>\n<p>2. Nerlynx (neratinib) [prescribing information]. Los Angeles, CA: Puma Biotechnology Inc; July 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11403":"<p><b>Title</b> Neratinib / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Neratinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of neratinib and strong CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 24 healthy volunteers described in the neratinib prescribing information, the strong CYP3A4 inducer rifampin decreased the neratinib (240 mg single dose) AUC and maximum serum concentration 87% and 76%, respectively.<sup>1</sup><br><br>Neratinib prescribing information states that because strong CYP3A4 inducers can decrease neratinib concentrations and lead to reduced efficacy, concomitant use of neratinib and strong CYP3A4 inducers should be avoided.<sup>1</sup><br><br>The mechanism of this interaction is likely rifampin-mediated induction of CYP3A4, an enzyme responsible for neratinib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Nerlynx (neratinib) [prescribing information]. Los Angeles, CA: Puma Biotechnology Inc; July 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11404":"<p><b>Title</b> Neratinib / CYP3A4 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may decrease the serum concentration of Neratinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of neratinib and moderate CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n</div> \n<p><b>Discussion</b> The use of moderate CYP3A4 inducers and neratinib has not been evaluated in a clinical study. However, in a pharmacokinetic study of 24 healthy volunteers described in the neratinib prescribing information, the strong CYP3A4 inducer rifampin decreased the neratinib (240 mg single dose) AUC and maximum serum concentration 87% and 76%, respectively.<sup>1</sup><br><br>Neratinib prescribing information states that because moderate CYP3A4 inducers may decrease neratinib concentrations and lead to reduced efficacy, concomitant use of neratinib and moderate CYP3A4 inducers should be avoided.<sup>1</sup><br><br>The mechanism of this interaction is likely rifampin-mediated induction of CYP3A4, an enzyme responsible for neratinib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Nerlynx (neratinib) [prescribing information]. Los Angeles, CA: Puma Biotechnology Inc; July 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11405":"<p><b>Title</b> Neratinib / Proton Pump Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Proton Pump Inhibitors may decrease the serum concentration of Neratinib. Specifically, proton pump inhibitors may reduce neratinib absorption. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of neratinib and proton pump inhibitors.</p>\n<div>\n <p><b>Proton Pump Inhibitors Interacting Members</b> Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, RABEprazole, Revaprazan</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 15 healthy volunteers, lansoprazole (30 mg once daily for 7 days) decreased the neratinib (240 mg single oral dose given on day 5) AUC and maximum serum concentration 65% and 71%, respectively.<sup>1</sup><br><br>Neratinib prescribing information states that because proton pump inhibitors (PPIs) can decrease neratinib concentrations and lead to reduced efficacy, concomitant use of neratinib and PPIs should be avoided.<sup>2</sup><br><br>The mechanism of this interaction has not been fully investigated, but is likely due to impaired absorption of neratinib. Like other tyrosine kinase inhibitors, neratinib appears to display pH-sensitive solubility, and is poorly absorbed at the elevated gastric pH caused by PPIs.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Keyvanjah K, DiPrimeo D, Li A, Obaidi M, Swearingen D, Wong A. Pharmacokinetics of neratinib during coadministration with lansoprazole in healthy subjects. <i>Br J Clin Pharmacol</i>. 2017;83(3):554-561. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27628584\">[PubMed 27628584]</a></p>\n<p>2. Nerlynx (neratinib) [prescribing information]. Los Angeles, CA: Puma Biotechnology Inc; July 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11406":"<p><b>Title</b> Neratinib / Histamine H2 Receptor Antagonists</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Histamine H2 Receptor Antagonists may decrease the serum concentration of Neratinib. Specifically, histamine H2 receptor antagonists may reduce neratinib absorption. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of histamine H2 receptor antagonists and neratinib.</p>\n<div>\n <p><b>Histamine H2 Receptor Antagonists Interacting Members</b> Cimetidine, Famotidine, Lafutidine, Nizatidine, RaNITIdine</p>\n</div> \n<p><b>Discussion</b> The use of histamine H2 receptor antagonists (H2RAs) and neratinib has not been evaluated in a clinical study. However, in a pharmacokinetic study of 15 healthy volunteers, lansoprazole (30 mg once daily for 7 days) decreased the neratinib (240 mg single oral dose given on day 5) AUC and maximum serum concentration 65% and 71%, respectively.<sup>1</sup><br><br>Neratinib prescribing information states that because H2RAs may decrease neratinib concentrations and lead to reduced efficacy, concomitant use of neratinib and H2RAs should be avoided.<sup>2</sup><br><br>The mechanism of this interaction has not been fully investigated, but is likely due to impaired absorption of neratinib. Like other tyrosine kinase inhibitors, neratinib appears to display pH-sensitive solubility, and is poorly absorbed at an elevated gastric pH.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Keyvanjah K, DiPrimeo D, Li A, Obaidi M, Swearingen D, Wong A. Pharmacokinetics of neratinib during coadministration with lansoprazole in healthy subjects. <i>Br J Clin Pharmacol</i>. 2017;83(3):554-561. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27628584\">[PubMed 27628584]</a></p>\n<p>2. Nerlynx (neratinib) [prescribing information]. Los Angeles, CA: Puma Biotechnology Inc; July 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11407":"<p><b>Title</b> Neratinib / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of Neratinib. Specifically, antacids may reduce neratinib absorption. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Separate the administration of neratinib and antacids by giving neratinib at least 3 hours after the antacid.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> The use of antacids and neratinib has not been evaluated in a clinical study. However, in a pharmacokinetic study of 15 healthy volunteers, lansoprazole (30 mg once daily for 7 days) decreased the neratinib (240 mg single oral dose given on day 5) AUC and maximum serum concentration 65% and 71%, respectively.<sup>1</sup><br><br>Neratinib prescribing information states that because antacids may decrease neratinib concentrations and lead to reduced efficacy, neratinib should be administered at least 3 hours after antacid administration.<sup>2</sup><br><br>The mechanism of this interaction has not been fully investigated, but is likely due to impaired absorption of neratinib. Like other tyrosine kinase inhibitors, neratinib appears to display pH-sensitive solubility, and is poorly absorbed at an elevated gastric pH.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Keyvanjah K, DiPrimeo D, Li A, Obaidi M, Swearingen D, Wong A. Pharmacokinetics of neratinib during coadministration with lansoprazole in healthy subjects. <i>Br J Clin Pharmacol</i>. 2017;83(3):554-561. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27628584\">[PubMed 27628584]</a></p>\n<p>2. Nerlynx (neratinib) [prescribing information]. Los Angeles, CA: Puma Biotechnology Inc; July 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11408":"<p><b>Title</b> Digoxin / Neratinib</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Neratinib may increase the serum concentration of Digoxin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased digoxin concentrations and effects if combined with neratinib. Decreased digoxin doses may be required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 18 healthy volunteers described in the neratinib prescribing information, multiple daily doses of neratinib increased the digoxin (0.5 mg single oral dose) AUC and maximum serum concentration 32% and 54%, respectively.<sup>1</sup><br><br>The mechanism of this interaction has not been fully investigated, but neratinib-mediated inhibition of P-glycoprotein, a transporter involved in digoxin disposition, likely contributes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Nerlynx (neratinib) [prescribing information]. Los Angeles, CA: Puma Biotechnology Inc; July 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11409":"<p><b>Title</b> Neratinib / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Neratinib. Cimetidine may decrease the serum concentration of Neratinib. Specifically, cimetidine may reduce neratinib absorption. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of neratinib and cimetidine.</p> \n<p><b>Discussion</b> The use of cimetidine and neratinib has not been evaluated in a clinical study. However, in a pharmacokinetic study of 15 healthy volunteers, lansoprazole (30 mg once daily for 7 days) decreased the neratinib (240 mg single oral dose given on day 5) AUC and maximum serum concentration 65% and 71%, respectively.<sup>1</sup> Neratinib prescribing information states that because histamine H2 receptor antagonists (H2RAs) may decrease neratinib concentrations and lead to reduced efficacy, concomitant use of neratinib and H2RAs should be avoided.<sup>2</sup><br><br>In a pharmacokinetic study of 22 healthy volunteers, the strong CYP3A4 inhibitor ketoconazole (400 mg once daily for 5 days) increased the neratinib (240 mg single dose given on day 2) AUC and maximum serum concentration 4.8-fold and 3.2-fold, respectively.<sup>3</sup> Neratinib prescribing information also states that because moderate CYP3A4 inhibitors may increase neratinib concentrations and lead to an increased risk of adverse effects, concomitant use of neratinib and moderate CYP3A4 inhibitors should be avoided.<sup>2</sup> Although neratinib product labeling lists cimetidine as an example of a moderate CYP3A4 inhibitor,<sup>2</sup> the majority of clinical data suggests that cimetidine is a weak CYP3A4 inhibitor.<sup>4,5</sup><br><br>The mechanism by which cimetidine may decrease concentration of neratinib has not been fully investigated, but is likely due to impaired absorption of neratinib. Like other tyrosine kinase inhibitors, neratinib appears to display pH-sensitive solubility, and is poorly absorbed at an elevated gastric pH. The mechanism by which cimetidine may increase neratinib concentrations is likely due to inhibition of CYP3A4, an enzyme responsible for neratinib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D. Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects. <i>Br J Clin Pharmacol</i>. 2011;71(4):522-527. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21395644\">[PubMed 21395644]</a></p>\n<p>2. Nerlynx (neratinib) [prescribing information]. Los Angeles, CA: Puma Biotechnology Inc; July 2017.</p>\n<p>3. Keyvanjah K, DiPrimeo D, Li A, Obaidi M, Swearingen D, Wong A. Pharmacokinetics of neratinib during coadministration with lansoprazole in healthy subjects. <i>Br J Clin Pharmacol</i>. 2017;83(3):554-561. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27628584\">[PubMed 27628584]</a></p>\n<p>4. Martinez C, Albet C, Aqundez JA, et al. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. <i>Clin Pharmacol Ther</i>. 1999;65(4):369-376. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10223772\">[PubMed 10223772]</a></p>\n<p>5. Friedman H, Greenblatt DJ, Burstein ES, Scavone JM, Harmatz JS, Shader RI. Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. <i>J Clin Pharmacol</i>. 1988;28(3):228-233. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3360971\">[PubMed 3360971]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11410":"<p><b>Title</b> Neratinib / Ciprofloxacin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ciprofloxacin (Systemic) may increase the serum concentration of Neratinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of neratinib and ciprofloxacin if possible. If combined, monitor for increased neratinib effects/toxicities.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 22 healthy volunteers, the strong CYP3A4 inhibitor ketoconazole (400 mg once daily for 5 days) increased the neratinib (240 mg single dose given on day 2) AUC and maximum serum concentration 4.8-fold and 3.2-fold, respectively.<sup>1</sup><br><br>Neratinib prescribing information states that because moderate CYP3A4 inhibitors may increase neratinib concentrations and lead to an increased risk of adverse effects, concomitant use of neratinib and moderate CYP3A4 inhibitors should be avoided.<sup>2</sup> Although neratinib product labeling lists cimetidine, ciprofloxacin, clotrimazole, cyclosporine, fluvoxamine, and tofisopam as examples of moderate CYP3A4 inhibitors,<sup>2</sup> the majority of clinical data suggests that these agents are more often classified as weak CYP3A4 inhibitors.<sup>3,4,5,6,7,8,9,10,11</sup><br><br>The mechanism of this interaction is likely ketoconazole-mediated inhibition of CYP3A4, an enzyme responsible for neratinib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D. Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects. <i>Br J Clin Pharmacol</i>. 2011;71(4):522-527. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21395644\">[PubMed 21395644]</a></p>\n<p>2. Nerlynx (neratinib) [prescribing information]. Los Angeles, CA: Puma Biotechnology Inc; July 2017.</p>\n<p>3. Martinez C, Albet C, Aqundez JA, et al. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. <i>Clin Pharmacol Ther</i>. 1999;65(4):369-376. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10223772\">[PubMed 10223772]</a></p>\n<p>4. Friedman H, Greenblatt DJ, Burstein ES, Scavone JM, Harmatz JS, Shader RI. Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. <i>J Clin Pharmacol</i>. 1988;28(3):228-233. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3360971\">[PubMed 3360971]</a></p>\n<p>5. Sriwiriyajan S, Samaeng M, Ridtitid W, Mahatthanatrakul W, Wongnawa M. Pharmacokinetic interactions between ciprofloxacin and itraconazole in healthy male volunteers. <i>Biopharm Drug Dispos</i>. 2011;32(3):168-174. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21360715\">[PubMed 21360715]</a></p>\n<p>6. Shahzadi A, Javed I, Aslam B, et al. Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers. <i>Pak J Pharm Sci</i>. 2011;24(1):63-68. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21190921\">[PubMed 21190921]</a></p>\n<p>7. Shord SS, Chan LN, Camp JR, et al. Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam. <i>Br J Clin Pharmacol</i>. 2010;69(2):160-166. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20233179\">[PubMed 20233179]</a></p>\n<p>8. Madsen JK, Jensen JD, Jensen LW, Pedersen EB. Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine. <i>Eur J Clin Pharmacol</i>. 1996;50(3):203-208. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8737760\">[PubMed 8737760]</a></p>\n<p>9. Lam YW, Alfaro CL, Ereshefsky L, Miller M. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. <i>J Clin Pharmacol</i>. 2003;43(11):1274-1282. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14551182\">[PubMed 14551182]</a></p>\n<p>10. Kashuba AD, Nafziger AN, Kearns GL, et al. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. <i>Clin Pharmacol Ther</i>. 1998;64(3):257-268. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9757149\">[PubMed 9757149]</a></p>\n<p>11. Drabant S, Toth M, Bereczki A, Bajnogel J, Tomlo J, Klebovich I. Effect of tofisopam on the single-oral-dose pharmacokinetics and pharmacodynamics of the cyp3a4 probe drug alprazolam. <i>Eur J Clin Pharmacol</i>. 2006;62(7):587-588. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16791582\">[PubMed 16791582]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11411":"<p><b>Title</b> Neratinib / Clotrimazole (Oral)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Clotrimazole (Oral) may increase the serum concentration of Neratinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of neratinib and clotrimazole if possible. If combined, monitor for increased neratinib effects/toxicities.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 22 healthy volunteers, the strong CYP3A4 inhibitor ketoconazole (400 mg once daily for 5 days) increased the neratinib (240 mg single dose given on day 2) AUC and maximum serum concentration 4.8-fold and 3.2-fold, respectively.<sup>1</sup><br><br>Neratinib prescribing information states that because moderate CYP3A4 inhibitors may increase neratinib concentrations and lead to an increased risk of adverse effects, concomitant use of neratinib and moderate CYP3A4 inhibitors should be avoided.<sup>2</sup> Although neratinib product labeling lists cimetidine, ciprofloxacin, clotrimazole, cyclosporine, fluvoxamine, and tofisopam as examples of moderate CYP3A4 inhibitors,<sup>2</sup> the majority of clinical data suggests that these agents are more often classified as weak CYP3A4 inhibitors.<sup>3,4,5,6,7,8,9,10,11</sup><br><br>The mechanism of this interaction is likely ketoconazole-mediated inhibition of CYP3A4, an enzyme responsible for neratinib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D. Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects. <i>Br J Clin Pharmacol</i>. 2011;71(4):522-527. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21395644\">[PubMed 21395644]</a></p>\n<p>2. Nerlynx (neratinib) [prescribing information]. Los Angeles, CA: Puma Biotechnology Inc; July 2017.</p>\n<p>3. Martinez C, Albet C, Aqundez JA, et al. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. <i>Clin Pharmacol Ther</i>. 1999;65(4):369-376. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10223772\">[PubMed 10223772]</a></p>\n<p>4. Friedman H, Greenblatt DJ, Burstein ES, Scavone JM, Harmatz JS, Shader RI. Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. <i>J Clin Pharmacol</i>. 1988;28(3):228-233. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3360971\">[PubMed 3360971]</a></p>\n<p>5. Sriwiriyajan S, Samaeng M, Ridtitid W, Mahatthanatrakul W, Wongnawa M. Pharmacokinetic interactions between ciprofloxacin and itraconazole in healthy male volunteers. <i>Biopharm Drug Dispos</i>. 2011;32(3):168-174. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21360715\">[PubMed 21360715]</a></p>\n<p>6. Shahzadi A, Javed I, Aslam B, et al. Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers. <i>Pak J Pharm Sci</i>. 2011;24(1):63-68. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21190921\">[PubMed 21190921]</a></p>\n<p>7. Shord SS, Chan LN, Camp JR, et al. Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam. <i>Br J Clin Pharmacol</i>. 2010;69(2):160-166. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20233179\">[PubMed 20233179]</a></p>\n<p>8. Madsen JK, Jensen JD, Jensen LW, Pedersen EB. Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine. <i>Eur J Clin Pharmacol</i>. 1996;50(3):203-208. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8737760\">[PubMed 8737760]</a></p>\n<p>9. Lam YW, Alfaro CL, Ereshefsky L, Miller M. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. <i>J Clin Pharmacol</i>. 2003;43(11):1274-1282. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14551182\">[PubMed 14551182]</a></p>\n<p>10. Kashuba AD, Nafziger AN, Kearns GL, et al. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. <i>Clin Pharmacol Ther</i>. 1998;64(3):257-268. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9757149\">[PubMed 9757149]</a></p>\n<p>11. Drabant S, Toth M, Bereczki A, Bajnogel J, Tomlo J, Klebovich I. Effect of tofisopam on the single-oral-dose pharmacokinetics and pharmacodynamics of the cyp3a4 probe drug alprazolam. <i>Eur J Clin Pharmacol</i>. 2006;62(7):587-588. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16791582\">[PubMed 16791582]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11412":"<p><b>Title</b> Neratinib / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may increase the serum concentration of Neratinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of neratinib and cyclosporine if possible. If combined, monitor for increased neratinib effects/toxicities.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 22 healthy volunteers, the strong CYP3A4 inhibitor ketoconazole (400 mg once daily for 5 days) increased the neratinib (240 mg single dose given on day 2) AUC and maximum serum concentration 4.8-fold and 3.2-fold, respectively.<sup>1</sup><br><br>Neratinib prescribing information states that because moderate CYP3A4 inhibitors may increase neratinib concentrations and lead to an increased risk of adverse effects, concomitant use of neratinib and moderate CYP3A4 inhibitors should be avoided.<sup>2</sup> Although neratinib product labeling lists cimetidine, ciprofloxacin, clotrimazole, cyclosporine, fluvoxamine, and tofisopam as examples of moderate CYP3A4 inhibitors,<sup>2</sup> the majority of clinical data suggests that these agents are more often classified as weak CYP3A4 inhibitors.<sup>3,4,5,6,7,8,9,10,11</sup><br><br>The mechanism of this interaction is likely ketoconazole-mediated inhibition of CYP3A4, an enzyme responsible for neratinib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D. Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects. <i>Br J Clin Pharmacol</i>. 2011;71(4):522-527. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21395644\">[PubMed 21395644]</a></p>\n<p>2. Nerlynx (neratinib) [prescribing information]. Los Angeles, CA: Puma Biotechnology Inc; July 2017.</p>\n<p>3. Martinez C, Albet C, Aqundez JA, et al. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. <i>Clin Pharmacol Ther</i>. 1999;65(4):369-376. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10223772\">[PubMed 10223772]</a></p>\n<p>4. Friedman H, Greenblatt DJ, Burstein ES, Scavone JM, Harmatz JS, Shader RI. Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. <i>J Clin Pharmacol</i>. 1988;28(3):228-233. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3360971\">[PubMed 3360971]</a></p>\n<p>5. Sriwiriyajan S, Samaeng M, Ridtitid W, Mahatthanatrakul W, Wongnawa M. Pharmacokinetic interactions between ciprofloxacin and itraconazole in healthy male volunteers. <i>Biopharm Drug Dispos</i>. 2011;32(3):168-174. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21360715\">[PubMed 21360715]</a></p>\n<p>6. Shahzadi A, Javed I, Aslam B, et al. Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers. <i>Pak J Pharm Sci</i>. 2011;24(1):63-68. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21190921\">[PubMed 21190921]</a></p>\n<p>7. Shord SS, Chan LN, Camp JR, et al. Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam. <i>Br J Clin Pharmacol</i>. 2010;69(2):160-166. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20233179\">[PubMed 20233179]</a></p>\n<p>8. Madsen JK, Jensen JD, Jensen LW, Pedersen EB. Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine. <i>Eur J Clin Pharmacol</i>. 1996;50(3):203-208. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8737760\">[PubMed 8737760]</a></p>\n<p>9. Lam YW, Alfaro CL, Ereshefsky L, Miller M. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. <i>J Clin Pharmacol</i>. 2003;43(11):1274-1282. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14551182\">[PubMed 14551182]</a></p>\n<p>10. Kashuba AD, Nafziger AN, Kearns GL, et al. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. <i>Clin Pharmacol Ther</i>. 1998;64(3):257-268. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9757149\">[PubMed 9757149]</a></p>\n<p>11. Drabant S, Toth M, Bereczki A, Bajnogel J, Tomlo J, Klebovich I. Effect of tofisopam on the single-oral-dose pharmacokinetics and pharmacodynamics of the cyp3a4 probe drug alprazolam. <i>Eur J Clin Pharmacol</i>. 2006;62(7):587-588. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16791582\">[PubMed 16791582]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11413":"<p><b>Title</b> Neratinib / FluvoxaMINE</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> FluvoxaMINE may increase the serum concentration of Neratinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of neratinib and fluvoxamine if possible. If combined, monitor for increased neratinib effects/toxicities.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 22 healthy volunteers, the strong CYP3A4 inhibitor ketoconazole (400 mg once daily for 5 days) increased the neratinib (240 mg single dose given on day 2) AUC and maximum serum concentration 4.8-fold and 3.2-fold, respectively.<sup>1</sup><br><br>Neratinib prescribing information states that because moderate CYP3A4 inhibitors may increase neratinib concentrations and lead to an increased risk of adverse effects, concomitant use of neratinib and moderate CYP3A4 inhibitors should be avoided.<sup>2</sup> Although neratinib product labeling lists cimetidine, ciprofloxacin, clotrimazole, cyclosporine, fluvoxamine, and tofisopam as examples of moderate CYP3A4 inhibitors,<sup>2</sup> the majority of clinical data suggests that these agents are more often classified as weak CYP3A4 inhibitors.<sup>3,4,5,6,7,8,9,10,11</sup><br><br>The mechanism of this interaction is likely ketoconazole-mediated inhibition of CYP3A4, an enzyme responsible for neratinib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D. Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects. <i>Br J Clin Pharmacol</i>. 2011;71(4):522-527. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21395644\">[PubMed 21395644]</a></p>\n<p>2. Nerlynx (neratinib) [prescribing information]. Los Angeles, CA: Puma Biotechnology Inc; July 2017.</p>\n<p>3. Martinez C, Albet C, Aqundez JA, et al. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. <i>Clin Pharmacol Ther</i>. 1999;65(4):369-376. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10223772\">[PubMed 10223772]</a></p>\n<p>4. Friedman H, Greenblatt DJ, Burstein ES, Scavone JM, Harmatz JS, Shader RI. Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. <i>J Clin Pharmacol</i>. 1988;28(3):228-233. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3360971\">[PubMed 3360971]</a></p>\n<p>5. Sriwiriyajan S, Samaeng M, Ridtitid W, Mahatthanatrakul W, Wongnawa M. Pharmacokinetic interactions between ciprofloxacin and itraconazole in healthy male volunteers. <i>Biopharm Drug Dispos</i>. 2011;32(3):168-174. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21360715\">[PubMed 21360715]</a></p>\n<p>6. Shahzadi A, Javed I, Aslam B, et al. Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers. <i>Pak J Pharm Sci</i>. 2011;24(1):63-68. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21190921\">[PubMed 21190921]</a></p>\n<p>7. Shord SS, Chan LN, Camp JR, et al. Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam. <i>Br J Clin Pharmacol</i>. 2010;69(2):160-166. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20233179\">[PubMed 20233179]</a></p>\n<p>8. Madsen JK, Jensen JD, Jensen LW, Pedersen EB. Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine. <i>Eur J Clin Pharmacol</i>. 1996;50(3):203-208. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8737760\">[PubMed 8737760]</a></p>\n<p>9. Lam YW, Alfaro CL, Ereshefsky L, Miller M. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. <i>J Clin Pharmacol</i>. 2003;43(11):1274-1282. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14551182\">[PubMed 14551182]</a></p>\n<p>10. Kashuba AD, Nafziger AN, Kearns GL, et al. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. <i>Clin Pharmacol Ther</i>. 1998;64(3):257-268. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9757149\">[PubMed 9757149]</a></p>\n<p>11. Drabant S, Toth M, Bereczki A, Bajnogel J, Tomlo J, Klebovich I. Effect of tofisopam on the single-oral-dose pharmacokinetics and pharmacodynamics of the cyp3a4 probe drug alprazolam. <i>Eur J Clin Pharmacol</i>. 2006;62(7):587-588. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16791582\">[PubMed 16791582]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11414":"<p><b>Title</b> Neratinib / Tofisopam</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Tofisopam may increase the serum concentration of Neratinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of neratinib and tofisopam if possible. If combined, monitor for increased neratinib effects/toxicities.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 22 healthy volunteers, the strong CYP3A4 inhibitor ketoconazole (400 mg once daily for 5 days) increased the neratinib (240 mg single dose given on day 2) AUC and maximum serum concentration 4.8-fold and 3.2-fold, respectively.<sup>1</sup><br><br>Neratinib prescribing information states that because moderate CYP3A4 inhibitors may increase neratinib concentrations and lead to an increased risk of adverse effects, concomitant use of neratinib and moderate CYP3A4 inhibitors should be avoided.<sup>2</sup> Although neratinib product labeling lists cimetidine, ciprofloxacin, clotrimazole, cyclosporine, fluvoxamine, and tofisopam as examples of moderate CYP3A4 inhibitors,<sup>2</sup> the majority of clinical data suggests that these agents are more often classified as weak CYP3A4 inhibitors.<sup>3,4,5,6,7,8,9,10,11</sup><br><br>The mechanism of this interaction is likely ketoconazole-mediated inhibition of CYP3A4, an enzyme responsible for neratinib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D. Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects. <i>Br J Clin Pharmacol</i>. 2011;71(4):522-527. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21395644\">[PubMed 21395644]</a></p>\n<p>2. Nerlynx (neratinib) [prescribing information]. Los Angeles, CA: Puma Biotechnology Inc; July 2017.</p>\n<p>3. Martinez C, Albet C, Aqundez JA, et al. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. <i>Clin Pharmacol Ther</i>. 1999;65(4):369-376. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10223772\">[PubMed 10223772]</a></p>\n<p>4. Friedman H, Greenblatt DJ, Burstein ES, Scavone JM, Harmatz JS, Shader RI. Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. <i>J Clin Pharmacol</i>. 1988;28(3):228-233. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3360971\">[PubMed 3360971]</a></p>\n<p>5. Sriwiriyajan S, Samaeng M, Ridtitid W, Mahatthanatrakul W, Wongnawa M. Pharmacokinetic interactions between ciprofloxacin and itraconazole in healthy male volunteers. <i>Biopharm Drug Dispos</i>. 2011;32(3):168-174. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21360715\">[PubMed 21360715]</a></p>\n<p>6. Shahzadi A, Javed I, Aslam B, et al. Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers. <i>Pak J Pharm Sci</i>. 2011;24(1):63-68. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21190921\">[PubMed 21190921]</a></p>\n<p>7. Shord SS, Chan LN, Camp JR, et al. Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam. <i>Br J Clin Pharmacol</i>. 2010;69(2):160-166. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20233179\">[PubMed 20233179]</a></p>\n<p>8. Madsen JK, Jensen JD, Jensen LW, Pedersen EB. Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine. <i>Eur J Clin Pharmacol</i>. 1996;50(3):203-208. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8737760\">[PubMed 8737760]</a></p>\n<p>9. Lam YW, Alfaro CL, Ereshefsky L, Miller M. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. <i>J Clin Pharmacol</i>. 2003;43(11):1274-1282. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14551182\">[PubMed 14551182]</a></p>\n<p>10. Kashuba AD, Nafziger AN, Kearns GL, et al. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. <i>Clin Pharmacol Ther</i>. 1998;64(3):257-268. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9757149\">[PubMed 9757149]</a></p>\n<p>11. Drabant S, Toth M, Bereczki A, Bajnogel J, Tomlo J, Klebovich I. Effect of tofisopam on the single-oral-dose pharmacokinetics and pharmacodynamics of the cyp3a4 probe drug alprazolam. <i>Eur J Clin Pharmacol</i>. 2006;62(7):587-588. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16791582\">[PubMed 16791582]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11415":"<p><b>Title</b> Chloroquine / Tamoxifen</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Tamoxifen may enhance the adverse/toxic effect of Chloroquine. Specifically, concomitant use of tamoxifen and chloroquine may increase the risk of retinal toxicity. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients annually for increased risk of retinal toxicity if chloroquine is combined with tamoxifen.</p> \n<p><b>Discussion</b> In a large study of hydroxychloroquine-treated patients, concomitant use of tamoxifen was associated with an increased risk for retinal toxicity (OR 4.59; 95% CI [2.05 to 10.27]).<sup>1</sup> The American Academy of Ophthalmology revised recommendations recommend careful dosing and regular annual screening (as opposed to screening every 5 years) for patients taking tamoxifen and chloroquine concomitantly.<sup>2</sup> Chloroquine prescribing information also recommends annual screening for retinal toxicity with the combination and recommends against concomitant use if possible.<sup>3</sup><br><br>The mechanism of the interaction has not been established, but tamoxifen alone is a known retinal toxin and adverse synergism with hydroxychloroquine may play a role.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. <i>JAMA Ophthalmol</i>. 2014;132(12):1453-1460. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25275721\">[PubMed 25275721]</a></p>\n<p>2. Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF; American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). <i>Ophthalmology</i>. 2016;123(6):1386-1394. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26992838\">[PubMed 26992838]</a></p>\n<p>3. Aralen (chloroquine) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; July 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11416":"<p><b>Title</b> Potassium Phosphate / Antacids</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction only applies to the oral administration of potassium phosphate.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of Potassium Phosphate. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider separating administration of antacids and oral potassium phosphate by at least 2 hours to decrease risk of a significant interaction. Patients using this combination should be monitored closely for response to potassium phosphate therapy.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> According to the potassium acid phosphate prescribing information, the use of magnesium-, calcium-, or aluminum-containing antacids in conjunction with phosphate preparations may result in reduced phosphate absorption, which could lead to decreased effectiveness.<sup>1</sup><br><br>The mechanism for this interaction is likely binding of the phosphate to the polyvalent cation, resulting in a non-absorbable compound. Separating administration of the potassium phosphate and the antacid by at least 2 hours may minimize the magnitude of any interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. K-Phos Original (potassium acid phosphate) [prescribing information]. Tampa, FL: Beach Pharmaceuticals; October 1998.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11417":"<p><b>Title</b> Salicylates / Potassium Phosphate</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Brand Name</b>: This interaction only applies to oral administratio of potassium acid phosphate (K-Phos) which is a urinary acidifying agent. Intravenous potassium phosphate intended for phosphate supplementation will have little effect on salicylate concentrations.</p></li>\n <li><p><b>Duration</b>: The significance of this interaction may be of greater significance with long-term or more chronic salicylate use than with short-term or intermittent use.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Potassium Phosphate may increase the serum concentration of Salicylates. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Increase monitoring for evidence of salicylate toxicity when a salicylate is used together with oral potassium phosphate.</p>\n<div>\n <p><b>Salicylates Interacting Members</b> Aminosalicylic Acid, Aspirin, Bismuth Subsalicylate, Choline Magnesium Trisalicylate, Choline Salicylate, Magnesium Salicylate, Salsalate, Sodium Salicylate, Triflusal</p>\n</div> \n<p><b>Discussion</b> The salicylates, as acidic compounds, exist in a less readily absorbed ionized form when in alkaline environments (as induced by antacids) and in a more easily absorbed non-ionized form when in acidic environments (as induced by agents like ammonium chloride or potassium acid phosphate). With regard to salicylate renal excretion, salicylate that is not reabsorbed from the filtrate is thus eliminated in the urine. The urinary excretion of aspirin has been shown to be significantly correlated with urinary pH, with increased excretion associated with increases in urine pH.<sup>1</sup> In support of these observations, several reports have described decreased serum salicylate concentrations with concurrent use of antacids, which can produce an alkaline urine, increasing the urinary excretion of salicylates.<sup>2,3,4</sup> Based on these data and the excretion properties of the salicylates, it is expected that concurrent use with an agent that acidifies the urine would conversely result in an increase in serum salicylate concentrations and to potentially greater physiologic salicylate effects.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Elliot Cham B, Dykman JH, Bochner F. Urinary excretion of aspirin. <i>Br J Clin Pharmacol</i>. 1982;14(4):562-564. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7138740\">[PubMed 7138740]</a></p>\n<p>2. Levy G, Lampman T, Kamath BL, et al. Decreased serum salicylate concentrations in children with rheumatic fever treated with antacid. <i>N Engl J Med</i>. 1975;293(7):323-325. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=239345\">[PubMed 239345]</a></p>\n<p>3. Hansten PD, Hayton WL. Effect of antacid and ascorbic acid on serum salicylate concentration. <i>J Clin Pharmacol</i>. 1980;20(5-6 Pt 1):326-331. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7400368\">[PubMed 7400368]</a></p>\n<p>4. Macpherson CR, Milne MD, Evans BM. The excretion of salicylate. <i>Br J Pharmacol Chemother</i>. 1955;10(4):484-489. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13276608\">[PubMed 13276608]</a></p>\n<p>5. K-Phos Original (potassium acid phosphate) [prescribing information]. Tampa, FL: Beach Pharmaceuticals; October 1998.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11418":"<p><b>Title</b> Voxilaprevir / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> RifAMPin may increase the serum concentration of Voxilaprevir. Specifically, a single dose of rifampin may increase voxilaprevir concentrations, while chronic daily use of rifampin may decrease voxilaprevir concentrations. RifAMPin may decrease the serum concentration of Voxilaprevir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid use of voxilaprevir and rifampin. This combination is listed as contraindicated in the sofosbuvir/velpatasvir/voxilaprevir prescribing information.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 24 healthy volunteers described in the prescribing information, rifampin (600 mg daily) decreased the voxilaprevir (100 mg single dose) AUC and maximum serum concentration (Cmax) 73% and 9%, respectively.<sup>1</sup> When a single dose of rifampin (600 mg) was given with a single dose of voxilaprevir (100 mg) the voxilaprevir AUC and Cmax increased 7.9-fold and 11.1-fold, respectively.<sup>1</sup><br><br>Prescribing information states that because single dose rifampin may increase voxilaprevir concentrations and daily rifampin may significantly decrease voxilaprevir concentrations, use of sofosbuvir/velpatasvir/voxilaprevir with any rifampin regimen is contraindicated.<sup>1</sup><br><br>The mechanism by which rifampin decreases voxilaprevir concentrations is likely due to rifampin-mediated induction of CYP3A4, an enzyme responsible for voxilaprevir metabolism. Single dose rifampin inhibits SLCOs (OATPs), transporters responsible for the hepatic uptake of voxilaprevir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Vosevi (sofosbuvir/velpatasvir/voxilaprevir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11419":"<p><b>Title</b> Voxilaprevir / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Voxilaprevir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of voxilaprevir and strong CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 24 healthy volunteers described in the prescribing information, rifampin (600 mg daily) decreased the voxilaprevir (100 mg single dose) AUC and maximum serum concentration 73% and 9%, respectively.<sup>1</sup><br><br>Prescribing information states that because strong CYP3A4 inducers may significantly reduce voxilaprevir concentrations and lead to reduced efficacy, concomitant use is not recommended.<sup>1</sup><br><br>The mechanism of this interaction is due to rifampin-mediated induction of CYP3A4, an enzyme responsible for voxilaprevir metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Vosevi (sofosbuvir/velpatasvir/voxilaprevir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11420":"<p><b>Title</b> Voxilaprevir / Atazanavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Atazanavir may increase the serum concentration of Voxilaprevir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of voxilaprevir and atazanavir.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the sofosbuvir/velpatasvir/voxilaprevir prescribing information, atazanavir/ritonavir (300 mg/100 mg) single dose increased the voxilaprevir AUC and maximum serum concentration 4.3-fold and 4.4-fold, respectively.<sup>1</sup><br><br>Prescribing information states that because atazanavir may increase voxilaprevir concentrations and lead to increased toxicities, coadministration of sofosbuvir/velpatasvir/voxilaprevir with atazanavir is not recommended.<sup>1</sup><br><br>The mechanism of this interaction is likely atazanavir-mediated inhibition of CYP3A4, an enzyme responsible for voxilaprevir metabolism. Inhibition of BCRP or SLCO (OATP) transporters may also contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Vosevi (sofosbuvir/velpatasvir/voxilaprevir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11421":"<p><b>Title</b> Voxilaprevir / Lopinavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Lopinavir may increase the serum concentration of Voxilaprevir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of voxilaprevir and lopinavir.</p> \n<p><b>Discussion</b> The effect of lopinavir on voxilaprevir concentrations has not been evaluated in a clinical study. However, according to data presented in the sofosbuvir/velpatasvir/voxilaprevir prescribing information, the effects of various strong CYP3A4 inhibitors on voxilaprevir concentrations have been evaluated in several pharmacokinetic studies.<sup>1</sup> The voxilaprevir AUC increased 2.4-fold with darunavir/ritonavir, 2.7-fold with cobicistat, 1.7-fold with ketoconazole, and 1.8-fold with voriconazole.<sup>1</sup> Coadministration with atazanavir/ritonavir lead to a greater (4.3-fold increase) in voxilaprevir AUC.<sup>1</sup> <br><br>Prescribing information states that sofosbuvir/velpatasvir/voxilaprevir should not be combined with atazanavir or lopinavir, but the pharmacokinetic changes seen with other strong CYP3A4 inhibitors are unlikely to be clinically significant, and can be combined without dose adjustment or additional monitoring.<sup>1</sup><br><br>The mechanism of this interaction is likely inhibition of CYP3A4, the enzyme responsible for voxilaprevir metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Vosevi (sofosbuvir/velpatasvir/voxilaprevir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11422":"<p><b>Title</b> Voxilaprevir / OATP1B1/SLCO1B1 Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> OATP1B1/SLCO1B1 Inhibitors may increase the serum concentration of Voxilaprevir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of voxilaprevir and SLCO1B1 (OATP1B1) inhibitors.</p>\n<div>\n <p><b>OATP1B1/SLCO1B1 Inhibitors Interacting Members</b> Cobicistat, CycloSPORINE (Systemic), Daclatasvir, Eltrombopag, Gemfibrozil, Glecaprevir and Pibrentasvir, Letermovir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, RifAMPin, Simeprevir, Teriflunomide, Velpatasvir, Voxilaprevir</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 24 healthy volunteers described in the prescribing information, coadministration of a single dose of rifampin (600 mg) and a single dose of voxilaprevir (100 mg) increased the voxilaprevir AUC and maximum serum concentration (Cmax) 7.9-fold and 11.1-fold, respectively.<sup>1</sup> In another study of 25 healthy volunteers, coadministration of cyclosporine (600 mg single dose) and voxilaprevir (100 mg single dose) increased the voxilaprevir AUC and Cmax 9.4-fold and 19-fold, respectively.<sup>1</sup><br><br>Prescribing information states that because SLCO1B1 (OATP1B1) inhibitors can significantly increase voxilaprevir concentrations and the risk for toxicities, concomitant use is not recommended.<sup>1</sup><br><br>The mechanisms of these interactions is likely inhibition of SLCO1B1 (OATP1B1), a transporter responsible for voxilaprevir hepatic uptake. Inhibition of SLCO1B3 (OATP1B3) may also contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Vosevi (sofosbuvir/velpatasvir/voxilaprevir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11423":"<p><b>Title</b> Rosuvastatin / Voxilaprevir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Voxilaprevir may increase the serum concentration of Rosuvastatin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of voxilaprevir and rosuvastatin.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the sofosbuvir/velpatasvir/voxilaprevir prescribing information, sofosbuvir/velpatasvir/voxilaprevir (400 mg/100 mg/200 mg) daily increased the rosuvastatin AUC and maximum serum concentration 18.9-fold and 7.4-fold, respectively.<sup>1</sup><br><br>Prescribing information states coadministration of sofosbuvir/velpatasvir/voxilaprevir and rosuvastatin may significantly increase rosuvastatin concentrations and lead to an increased risk of myopathy and rhabdomyolysis.<sup>1</sup> Concomitant use is not recommended.<sup>1</sup> <br><br>The suspected primary mechanism of this interaction is likely voxilaprevir-mediated inhibition of SLCO1B1 and SLCO1B3 (OATP1B1 and OATP1B3), transporters responsible for the hepatic uptake of rosuvastatin, as well as voxilaprevir-mediated inhibition of BCRP, a transporter responsible for rosuvastatin disposition.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Vosevi (sofosbuvir/velpatasvir/voxilaprevir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11424":"<p><b>Title</b> Pitavastatin / Voxilaprevir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Voxilaprevir may increase the serum concentration of Pitavastatin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of voxilaprevir and pitavastatin.</p> \n<p><b>Discussion</b> In 2 pharmacokinetic studies described in the sofosbuvir/velpatasvir/voxilaprevir prescribing information, sofosbuvir/velpatasvir/voxilaprevir (400 mg/100 mg/200 mg) daily increased the pravastatin AUC and maximum serum concentration (Cmax) 1.9-fold and 2.2-fold, respectively, and increased the rosuvastatin AUC and Cmax 18.9-fold and 7.4-fold, respectively.<sup>1</sup><br><br>Prescribing information states that sofosbuvir/velpatasvir/voxilaprevir should not be combined with pitavastatin; this combination could lead to increased pitavastatin concentrations and an increased risk of myopathy or rhabdomyolysis.<sup>1</sup><br><br>The suspected primary mechanism of this interaction is likely voxilaprevir-mediated inhibition of SLCO1B1 and SLCO1B3 (OATP1B1 and OATP1B3), transporters responsible for the hepatic uptake of pitavastatin. Inhibition of BCRP may also contribute, particularly to the significant interaction seen with rosuvastatin.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Vosevi (sofosbuvir/velpatasvir/voxilaprevir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11425":"<p><b>Title</b> HMG-CoA Reductase Inhibitors (Statins) / Voxilaprevir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Voxilaprevir may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use the lowest statin dose possible if combined with voxilaprevir and monitor patients for increased statin effects/toxicities (eg, myopathy, rhabdomyolysis). Avoid concomitant use of voxilaprevir with rosuvastatin or pitavastatin, and limit pravastatin doses to 40 mg daily.</p>\n<div>\n <p><b>HMG-CoA Reductase Inhibitors (Statins) Interacting Members</b> AtorvaSTATin, Fluvastatin, Lovastatin, Pitavastatin, Pravastatin, Red Yeast Rice, Rosuvastatin, Simvastatin</p>\n</div> \n<p><b>Discussion</b> In 2 pharmacokinetic studies described in the sofosbuvir/velpatasvir/voxilaprevir prescribing information, sofosbuvir/velpatasvir/voxilaprevir (400 mg/100 mg/200 mg) daily increased the pravastatin AUC and maximum serum concentration (Cmax) 1.9-fold and 2.2-fold, respectively, and increased the rosuvastatin AUC and Cmax 18.9-fold and 7.4-fold, respectively.<sup>1</sup><br><br>Prescribing information states that statins should be used at the lowest possible doses if combined with sofosbuvir/velpatasvir/voxilaprevir and patients should be monitored for increased statin toxicities, including rhabdomyolysis.<sup>1</sup> Sofosbuvir/velpatasvir/voxilaprevir should not be combined with rosuvastatin or pitavastatin. If it is combined with pravastatin, the dose of pravastatin should not exceed 40 mg daily.<sup>1</sup><br><br>The suspected primary mechanism of this interaction is likely voxilaprevir-mediated inhibition of SLCO1B1 and SLCO1B3 (OATP1B1 and OATP1B3), transporters responsible for the hepatic uptake of statins. Inhibition of BCRP may also contribute, particularly to the significant interaction seen with rosuvastatin.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Vosevi (sofosbuvir/velpatasvir/voxilaprevir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11426":"<p><b>Title</b> BCRP/ABCG2 Substrates / Voxilaprevir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Voxilaprevir may increase the serum concentration of BCRP/ABCG2 Substrates. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concomitant use of voxilaprevir and BCRP substrates is not recommended.</p>\n<div>\n <p><b>BCRP/ABCG2 Substrates Interacting Members</b> Glecaprevir and Pibrentasvir, PAZOPanib, Rosuvastatin, SulfaSALAzine, Topotecan</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the sofosbuvir/velpatasvir/voxilaprevir prescribing information, sofosbuvir/velpatasvir/voxilaprevir (400 mg/100 mg/200 mg) daily increased the BCRP substrate rosuvastatin AUC and maximum serum concentration 18.9-fold and 7.4-fold, respectively.<sup>1</sup><br><br>Prescribing information states coadministration of sofosbuvir/velpatasvir/voxilaprevir with BCRP substrates may increase concentrations of BCRP substrates; concomitant use is not recommended.<sup>1</sup> <br><br>The suspected primary mechanism of this interaction is likely voxilaprevir-mediated inhibition of BCRP, a transporter responsible for rosuvastatin disposition. Voxilaprevir-mediated inhibition of SLCO1B1 and SLCO1B3 (OATP1B1 and OATP1B3), transporters responsible for the hepatic uptake of rosuvastatin, may also contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Vosevi (sofosbuvir/velpatasvir/voxilaprevir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11427":"<p><b>Title</b> Voxilaprevir / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Voxilaprevir. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action is required when voxilaprevir is combined with most strong CYP3A4 inhibitors. Avoid use with atazanavir and lopinavir.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> According to data presented in the sofosbuvir/velpatasvir/voxilaprevir prescribing information, the effects of various strong CYP3A4 inhibitors on voxilaprevir concentrations have been evaluated in several pharmacokinetic studies.<sup>1</sup> The voxilaprevir AUC increased 2.4-fold with darunavir/ritonavir, 2.7-fold with cobicistat, 1.7-fold with ketoconazole, and 1.8-fold with voriconazole.<sup>1</sup> Coadministration with atazanavir/ritonavir lead to a greater (4.3-fold increase) in voxilaprevir AUC.<sup>1</sup> <br><br>Prescribing information states that sofosbuvir/velpatasvir/voxilaprevir should not be combined with atazanavir or lopinavir, but the pharmacokinetic changes seen with other strong CYP3A4 inhibitors are unlikely to be clinically significant, and can be combined without dose adjustment or additional monitoring.<sup>1</sup><br><br>The mechanism of this interaction is likely inhibition of CYP3A4, the enzyme responsible for voxilaprevir metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Vosevi (sofosbuvir/velpatasvir/voxilaprevir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11428":"<p><b>Title</b> Ibrutinib / Ciprofloxacin (Systemic)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: The management of this interaction differs when ibrutinib is used for the treatment of B-cell malignancies versus when ibrutinib is used for the treatment of graft versus host disease.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ciprofloxacin (Systemic) may increase the serum concentration of Ibrutinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> When ibrutinib is used for the treatment of B-cell malignancies, consider decreasing the ibrutinib dose to 140 mg daily when combined ciprofloxacin.<br><br>When ibrutinib is used for the treatment of graft versus host disease, no preemptive dose reduction is recommended when combined with ciprofloxacin. Patients should be monitored closely for ibrutinib toxicities and ibrutinib dose reductions should occur as needed based on adverse reactions.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 8 healthy volunteers, the pharmacokinetics of ibrutinib (560 mg single dose) were compared with the pharmacokinetics of ibrutinib (140 mg single dose) combined with the moderate CYP3A4 inhibitor grapefruit juice (240 mL single dose).<sup>1</sup> The dose-normalized ibrutinib maximum serum concentration (Cmax) and AUC increased 3.5-fold and 2.2-fold, respectively.<sup>1</sup> In a separate pharmacokinetic study described in the ibrutinib prescribing information, multiple doses of erythromycin (to achieve steady state) increased the ibrutinib Cmax and AUC 3.4-fold and 3-fold, respectively.<sup>2</sup><br><br>Ibrutinib prescribing information states that when ibrutinib is used for the treatment of B-cell malignancies, the ibrutinib dose should be decreased to 140 mg daily when combined with moderate CYP3A4 inhibitors.<sup>2</sup> When ibrutinib is used for the treatment of graft versus host disease, no preemptive dose reduction is recommended when combined with moderate CYP3A4 inhibitors, but patients should be monitored closely for ibrutinib toxicities and ibrutinib dose reductions should occur as needed based on adverse reactions.<sup>2</sup> Although ibrutinib product labeling lists cimetidine, ciprofloxacin, clotrimazole, cyclosporine, fluvoxamine, and tofisopam as examples of moderate CYP3A4 inhibitors,<sup>2</sup> the majority of clinical data suggests that these agents are more often classified as weak CYP3A4 inhibitors.<sup>3,4,5,6,7,8,9,10,11</sup><br><br>The mechanism of this interaction is likely due to inhibition of CYP3A4, an enzyme responsible for ibrutinib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. de Jong J, Skee D, Murphy J, et al. Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants. <i>Pharmacol Res Perspect</i>. 2015;3(4):e00156. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26171235\">[PubMed 26171235]</a></p>\n<p>2. Imbruvica (ibrutinib) [prescribing information]. Horsham, PA: Janssen Biotech Inc; August 2017.</p>\n<p>3. Martinez C, Albet C, Aqundez JA, et al. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. <i>Clin Pharmacol Ther</i>. 1999;65(4):369-376. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10223772\">[PubMed 10223772]</a></p>\n<p>4. Friedman H, Greenblatt DJ, Burstein ES, Scavone JM, Harmatz JS, Shader RI. Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. <i>J Clin Pharmacol</i>. 1988;28(3):228-233. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3360971\">[PubMed 3360971]</a></p>\n<p>5. Sriwiriyajan S, Samaeng M, Ridtitid W, Mahatthanatrakul W, Wongnawa M. Pharmacokinetic interactions between ciprofloxacin and itraconazole in healthy male volunteers. <i>Biopharm Drug Dispos</i>. 2011;32(3):168-174. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21360715\">[PubMed 21360715]</a></p>\n<p>6. Shahzadi A, Javed I, Aslam B, et al. Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers. <i>Pak J Pharm Sci</i>. 2011;24(1):63-68. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21190921\">[PubMed 21190921]</a></p>\n<p>7. Shord SS, Chan LN, Camp JR, et al. Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam. <i>Br J Clin Pharmacol</i>. 2010;69(2):160-166. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20233179\">[PubMed 20233179]</a></p>\n<p>8. Madsen JK, Jensen JD, Jensen LW, Pedersen EB. Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine. <i>Eur J Clin Pharmacol</i>. 1996;50(3):203-208. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8737760\">[PubMed 8737760]</a></p>\n<p>9. Lam YW, Alfaro CL, Ereshefsky L, Miller M. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. <i>J Clin Pharmacol</i>. 2003;43(11):1274-1282. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14551182\">[PubMed 14551182]</a></p>\n<p>10. Kashuba AD, Nafziger AN, Kearns GL, et al. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. <i>Clin Pharmacol Ther</i>. 1998;64(3):257-268. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9757149\">[PubMed 9757149]</a></p>\n<p>11. Drabant S, Toth M, Bereczki A, Bajnogel J, Tomlo J, Klebovich I. Effect of tofisopam on the single-oral-dose pharmacokinetics and pharmacodynamics of the cyp3a4 probe drug alprazolam. <i>Eur J Clin Pharmacol</i>. 2006;62(7):587-588. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16791582\">[PubMed 16791582]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11429":"<p><b>Title</b> Secretin / Histamine H2 Receptor Antagonists</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Histamine H2 Receptor Antagonists may diminish the diagnostic effect of Secretin. Specifically, use of H2-Antagonists may cause a hyperresponse in gastrin secretion in response to secretin stimulation testing, falsely suggesting gastrinoma. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of histamine H2-antagonists (H2RAs) and secretin. Discontinue H2RAs at least 2 days prior to secretin administration.</p>\n<div>\n <p><b>Histamine H2 Receptor Antagonists Interacting Members</b> Cimetidine, Famotidine, Lafutidine, Nizatidine, RaNITIdine</p>\n</div> \n<p><b>Discussion</b> Secretin prescribing information states that patients receiving histamine H2-antagonists (H2RAs) or proton pump inhibitors at the time of stimulation testing with secretin to aid in the diagnosis of gastrinoma may be hyperresponsive to secretin stimulation, falsely suggesting gastrinoma.<sup>1</sup> Discontinue H2RAs at least 2 days prior to secretin stimulation testing.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Chirhostim (secretin) [prescribing information]. Burtonsville, MD: ChiRhoClin, Inc; July 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11430":"<p><b>Title</b> Secretin / Proton Pump Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Proton Pump Inhibitors may diminish the diagnostic effect of Secretin. Specifically, use of PPIs may cause a hyperresponse in gastrin secretion in response to secretin stimulation testing, falsely suggesting gastrinoma. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of proton pump inhibitors (PPIs) and secretin. Discontinue PPIs several weeks prior to secretin administration. Stop omeprazole and esomeprazole 14 days prior to secretin administration. Stop lansoprazole and dexlansoprazole 30 days prior to secretin administration. No specific dose separation is suggested for rabeprazole or pantoprazole.</p>\n<div>\n <p><b>Proton Pump Inhibitors Interacting Members</b> Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, RABEprazole, Revaprazan</p>\n</div> \n<p><b>Discussion</b> Secretin prescribing information states that patients receiving histamine H2-antagonists (H2RAs) or proton pump inhibitors (PPIs) at the time of stimulation testing with secretin to aid in the diagnosis of gastrinoma may be hyperresponsive to secretin stimulation, falsely suggesting gastrinoma.<sup>1</sup> Avoid concomitant use of PPIs and secretin, and discontinue PPIs several weeks prior to secretin administration, with the duration of separation determined by the specific PPI.<sup>1</sup> Stop omeprazole and esomeprazole 14 days prior to secretin administration.<sup>2,3</sup> Stop lansoprazole and dexlansoprazole 30 days prior to secretin administration.<sup>4,5</sup> No specific dose separation is suggested for rabeprazole or pantoprazole.<sup>6,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Chirhostim (secretin) [prescribing information]. Burtonsville, MD: ChiRhoClin Inc; July 2017.</p>\n<p>2. Prilosec (omeprazole) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; December 2016.</p>\n<p>3. Nexim (esomeprazole) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; December 2016.</p>\n<p>4. Prevacid (lansoprazole) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; October 2016.</p>\n<p>5. Dexilant (dexlansoprazole) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; October 2016.</p>\n<p>6. Aciphex (rabeprazole) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; October 2016. </p>\n<p>7. Protonix (pantoprazole) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; July 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11431":"<p><b>Title</b> Thyroid Products / Amiodarone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Amiodarone may diminish the therapeutic effect of Thyroid Products. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor the effectiveness of thyroid products, such as clinical signs and symptoms of hypothyroidism and/or serum thyroid stimulating hormone (TSH) concentrations, when starting or stopping amiodarone.</p>\n<div>\n <p><b>Thyroid Products Interacting Members</b> Levothyroxine, Liothyronine, Liotrix, Thyroid, Desiccated</p>\n</div> \n<p><b>Discussion</b> A case report describes a 73-year-old female with primary hypothyroidism who was euthyroid (TSH level 0.5 to 5 mU/L) while taking levothyroxine 0.75 mg orally daily for several years before being started on amiodarone (800 mg orally daily tapered to 200 mg daily) for paroxysmal atrial tachycardia.<sup>1</sup> Within the first 3 months of concomitant amiodarone and levothyroxine use, the patient developed symptoms consistent with hypothyroidism (fatigue, weakness, cold intolerance, hyponatremia). Laboratory tests revealed an elevated TSH level (20 to 30 mU/L). The TSH level decreased to 4.2 mU/L and the symptoms of hypothyroidism resolved after levothyroxine was incrementally increased to 0.112 mg daily while amiodarone was maintained at 200 mg/daily. <br><br>Another case, reported in the same publication, describes an 83-year old male with primary hypothyroidism who was euthyroid (TSH level 0.5 to 5 mU/L) while taking levothyroxine 0.1 mg orally daily for several years before beginning amiodarone 600 mg orally daily tapered to 200 mg daily for refractory ventricular tachycardia.<sup>1</sup> Over an undefined duration of time, the patient’s TSH level progressively increased to 22 mU/L; however, no additional signs or symptoms of hypothyroidism were appreciated.<br><br>The mechanism of this possible interaction is unknown, but impaired conversion of thyroxine (T4) to 3,5,3’-triiodothyronine (T3) and reduced cellular uptake of T3 and T4 may contribute.<sup>2,3,4,5</sup> Lastly, because amiodarone use has been associated with the development of hypothyroidism,<sup>5</sup> the potential need for increased levothyroxine dosages with amiodarone use may be the result of worsening thyroid function as opposed to a true drug interaction leading to decreased thyroid product effectiveness.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Figge J, Dluhy RG. Amiodarone-induced elevation of thyroid stimulating hormone in patients receiving levothyroxine for primary hypothyroidism. <i>Ann Intern Med</i>. 1990;113(7):553-555. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2393210\">[PubMed 2393210]</a></p>\n<p>2. Burger A, Dinichert D, Nicod P, et al. Effect of amiodarone on serum triiodothyronine, reverse triiodothyronine, thyroxin, and thyrotropin. A drug influencing peripheral metabolism of thyroid hormones. <i>J Clin Invest</i>. 1976;58(2):255-259. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=783194\">[PubMed 783194]</a></p>\n<p>3. Melmed S, Nademanee K, Reed AW, et al. Hyperthyroxinemia with bradycardia and normal thyrotropin secretion after chronic amiodarone administration. <i>J Clin Endocrinol Metab</i>. 1981;53(5):997-1001. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7287882\">[PubMed 7287882]</a></p>\n<p>4. Norman MF, Lavin TN. Antagonism of thyroid hormone action by amiodarone in rat pituitary tumor cells. <i>J Clin Invest</i>. 1989;83(1):306-313. [Pub Med 2910914]</p>\n<p>5. Nexterone (amiodarone HCl) [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; November 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11432":"<p><b>Title</b> Isoniazid / Propiverine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Propiverine may enhance the hypotensive effect of Isoniazid. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action is required, but be aware that this combination may lead to reduced blood pressure.</p> \n<p><b>Discussion</b> Propiverine product labeling states that in isoniazid treated patients, the use of propiverine may result in reduced blood pressure.<sup>1,2,3</sup> The mechanism of this interaction is unknown and no published studies have evaluated this drug combination.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Detrunorm (propiverine) tablets [summary of product characteristics]. London, United Kingdom: Amdipharm UK Limited; August 2014.</p>\n<p>2. Detrunorm XL (propiverine) modified-release capsules [summary of product characteristics]. London, United Kingdom: Amdipharm UK Limited; June 2014.</p>\n<p>3. Mictoryl (propiverine) [product monograph]. Blainville, Quebec, Canada: Duchesnay Inc; December 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11433":"<p><b>Title</b> Amantadine / Propiverine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Propiverine may enhance the adverse/toxic effect of Amantadine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased amantadine toxicities (eg, dry mouth, urinary retention, constipation) if combined with propiverine.</p> \n<p><b>Discussion</b> Propiverine product labeling states that the combination of propiverine and amantadine may lead to increased amantadine effects.<sup>1,2,3</sup> Although amantadine has not been shown to possess direct anticholinergic activity, clinically, it exhibits anticholinergic-like side effects (dry mouth, urinary retention, and constipation) that may be enhanced or exacerbated when combined with the anticholinergic agent propiverine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Detrunorm (propiverine) tablets [summary of product characteristics]. London, United Kingdom: Amdipharm UK Limited; August 2014.</p>\n<p>2. Detrunorm XL (propiverine) modified-release capsules [summary of product characteristics]. London, United Kingdom: Amdipharm UK Limited; June 2014.</p>\n<p>3. Mictoryl (propiverine) [product monograph]. Blainville, Quebec, Canada: Duchesnay Inc; December 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11434":"<p><b>Title</b> CycloSPORINE (Systemic) / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor clinical cyclosporine response closely and frequently monitor cyclosporine serum concentrations with concurrent use of any strong CYP3A4 inhibitor. Cyclosporine dose reductions and/or prolongation of the dosing interval will likely be required.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> Serum cyclosporine concentrations have been reported to increase as much as tenfold in transplant patients following the initiation of azole antifungal agents.<sup>1,2,3</sup> In some cases, cyclosporine dose reductions as much as 85% were needed to account for this interaction. These drug combinations have been implemented, at times, to exploit the interaction for its cost-saving effects.<sup>4</sup><br><br>The dose-normalized cyclosporine AUC was increased by an average of 4.6-fold when cyclosporine (100 mg x 1 alone, 10 mg x 1 on day 8 of telaprevir) was given to subjects (n=9) being treated with telaprevir (750 mg every 8 hours x 11 days).<sup>5,6</sup><br><br>Similarly, the cyclosporine AUC and maximum serum concentration (Cmax) were an average of 2.7-fold and 2-fold higher, respectively, when a single dose of cyclosporine (100 mg) was given to subjects receiving boceprevir (800 mg 3 times daily for 7 days).<sup>7,8</sup> <br><br>Lower, but still significant, increases in serum cyclosporine concentrations have been reported with the use of concomitant protease inhibitor therapy. One case series describes the initiation of ritonavir-boosted protease inhibitor therapy in 3 patients receiving cyclosporine as part of a post-liver transplant immunosuppressive regimen.<sup>9</sup> Two patients received lopinavir/ritonavir, and one patient received indinavir/ritonavir. The addition of protease inhibitor therapy necessitated a 5% to 20% reduction in baseline cyclosporine dose to maintain therapeutic trough concentrations.<sup>9</sup><br> <br>The cyclosporine prescribing information cautions that cyclosporine dose adjustment to achieve desired cyclosporine concentrations is essential with the concurrent use of drugs that significantly alter cyclosporine concentrations.<sup>10</sup> The inhibition of CYP3A4 likely accounts for much of these reported changes, but inhibition of p-glycoprotein or possibly other transporters may also contribute to the observed changes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. First MR, Schroeder TJ, Weiskittel P, et al. Concomitant administration of cyclosporin and ketoconazole in renal transplant recipients. <i>Lancet</i>. 1989;2(8673):1198-1201. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2572912\">[PubMed 2572912]</a></p>\n<p>2. First MR, Schroeder TJ, Alexander JW, et al. Cyclosporine dose reduction by ketoconazole administration in renal transplant recipients. <i>Transplantation</i>. 1991;51(2):365-370. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1994529\">[PubMed 1994529]</a></p>\n<p>3. First MR, Schroeder TJ, Michael A, et al. Cyclosporine-ketoconazole interaction. Long-term follow-up and preliminary results of a randomized trial. <i>Transplantation</i>. 1993;55(5):1000-1004. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8497871\">[PubMed 8497871]</a></p>\n<p>4. el-Husseini A, el-Basuony F, Mahmoud I, et al. Co-administration of cyclosporine and ketoconazole in idiopathic childhood nephrosis. <i>Pediatr Nephrol</i>. 2004;19(9):976-981. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15241676\">[PubMed 15241676]</a></p>\n<p>5. Incivek (telaprevir) [prescribing information]. Cambridge, MA: Vertex Pharmaceuticals Incorporated; October 2013.</p>\n<p>6. Garg V, van Heeswijk R, Lee JE, et al. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. <i>Hepatology</i>. 2011;54(1):20-27. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21618566\">[PubMed 21618566]</a></p>\n<p>7. Victrelis (boceprevir). [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc; January 2017.</p>\n<p>8. Hulskotte E, Gupta S, Xuan F, et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. <i>Hepatology</i>. 2012;56(5):1622-1630. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22576324\">[PubMed 22576324]</a></p>\n<p>9. Vogel M, Voigt E, Michaelis HC, et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. <i>Liver Transpl</i>. 2004;10(7):939-944. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15237382\">[PubMed 15237382]</a></p>\n<p>10. Neoral (cyclosporine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11435":"<p><b>Title</b> Celiprolol / P-glycoprotein/ABCB1 Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Celiprolol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased celiprolol effects/toxicities (eg, hypotension, bradycardia) if combined with P-glycoprotein inhibitors. Decreased celiprolol doses may be required.</p>\n<div>\n <p><b>P-glycoprotein/ABCB1 Inhibitors Interacting Members</b> Amiodarone, Azithromycin (Systemic), Carvedilol, Clarithromycin, CycloSPORINE (Systemic), Daclatasvir, Dronedarone, Eliglustat, Erythromycin (Systemic), Flibanserin, Glecaprevir and Pibrentasvir, Itraconazole, Ivacaftor, Ketoconazole (Systemic), Lapatinib, Ledipasvir, Neratinib, Ombitasvir, Paritaprevir, and Ritonavir, Propafenone, QuiNIDine, QuiNINE, Ranolazine, Ritonavir, Rolapitant, Simeprevir, Telaprevir, Velpatasvir, Vemurafenib, Verapamil</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 healthy volunteers, itraconazole (200 mg twice daily x 5 doses) increased the celiprolol (100 mg single dose) AUC and maximum serum concentration 81% and 33%, respectively.<sup>1</sup><br><br>The suspected primary mechanism of this interaction is itraconazole-mediated inhibition of P-glycoprotein, a transporter responsible for celiprolol distribution.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lilja JJ, Backman JT, Laitila J, Luurila H, Neuvonen PJ. Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. <i>Clin Pharmacol Ther</i>. 2003;73(3):192-198. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12621384\">[PubMed 12621384]</a></p>\n<p>2. Selectol (celiprolol) [KR product information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200001290. Accessed July 13, 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11436":"<p><b>Title</b> Celiprolol / P-glycoprotein/ABCB1 Inducers</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Celiprolol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased celiprolol efficacy if combined with P-glycoprotein inducers. Increased celiprolol doses may be required.</p>\n<div>\n <p><b>P-glycoprotein/ABCB1 Inducers Interacting Members</b> Apalutamide, Fosphenytoin, Phenytoin, RifAMPin, St John's Wort</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 10 healthy volunteers, rifampin (600 mg daily x 5 days) decreased the celiprolol (200 mg single dose) AUC and maximum serum concentration an average of 56% and 34%, respectively.<sup>1</sup><br><br>The suspected primary mechanism of this interaction is rifampin-mediated induction of P-glycoprotein, a transporter involved in celiprolol disposition.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lilja JJ, Niemi M, Neuvonen PJ. Rifampicin reduces plasma concentrations of celiprolol. <i>Eur J Clin Pharmacol</i>. 2004;59(11):819-824. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14614579\">[PubMed 14614579]</a></p>\n<p>2. Selectol (celiprolol) [KR product information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200001290. Accessed July 13, 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11437":"<p><b>Title</b> Celiprolol / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Grapefruit Juice may decrease the serum concentration of Celiprolol. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Patients should avoid consumption of grapefruit juice and orange juice during celiprolol therapy.</p> \n<p><b>Discussion</b> In 3 separate pharmacokinetic studies of healthy volunteers (N = 7 to 30), grapefruit juice (200 mL 3 to 4 times daily) decreased the celiprolol (100 mg single dose) AUC and maximum serum concentration (Cmax) 75% to 85% and 82% to 95%, respectively.<sup>1,2,3</sup> In another pharmacokinetic study of 10 healthy volunteers, orange juice (200 mL 3 times daily) decreased the celiprolol (100 mg single dose) AUC and Cmax 83% and 89%, respectively.<sup>4</sup><br><br>Although this drug interaction is not mentioned in all celiprolol product labels, at least 1 product label recommends that patients avoid consumption of grapefruit juice and orange juice when taking celiprolol.<sup>5</sup><br><br>The primary mechanism of this interaction is likely citrus juice-mediated inhibition of SLCO2B1 (OATP2B1), a transporter responsible for intestinal uptake and absorption of celiprolol.<sup>1,2,3,4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lilja JJ, Backman JT, Laitila J, Luurila H, Neuvonen PJ. Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. <i>Clin Pharmacol Ther</i>. 2003;73(3):192-198. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12621384\">[PubMed 12621384]</a></p>\n<p>2. Tanaka S, Uchida S, Miyakawa S, et al. Comparison of inhibitory duration of grapefruit juice on organic anion-transporting polypeptide and cytochrome P450 3A4. <i>Biol Pharm Bull</i>. 2013;36(12):1936-1941. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24292052\">[PubMed 24292052]</a></p>\n<p>3. Ieiri I, Doi Y, Maeda K, et al. Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose. <i>J Clin Pharmacol</i>. 2012;52(7):1078-1089. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21593283\">[PubMed 21593283]</a></p>\n<p>4. Lilja JJ, Juntti-Patinen L, Neuvonen PJ. Orange juice substantially reduces the bioavailability of the beta-adrenergic-blocking agent celiprolol. <i>Clin Pharmacol Ther</i>. 2004;75(3):184-190. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15001969\">[PubMed 15001969]</a></p>\n<p>5. Selectol (celiprolol) [KR product information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200001290. Accessed July 13, 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11438":"<p><b>Title</b> Celiprolol / Verapamil</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Verapamil may enhance the bradycardic effect of Celiprolol. Verapamil may increase the serum concentration of Celiprolol. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concomitant use of verapamil and celiprolol is not recommended, particularly in patients with pre-existing conduction abnormalities. When changing from verapamil to celiprolol and vice versa, a period between stopping one drug and starting the other is recommended. Patients should be monitored closely for bradycardia and hypotension if these agents are combined.</p> \n<p><b>Discussion</b> Celiprolol product labeling states that because celiprolol and verapamil slow atrioventricular conduction and depress myocardial contractility, their combined use will likely result in additive effects, such as bradycardia and/or hypotension.<sup>1,2</sup> Additionally, verapamil is a P-glycoprotein inhibitor and has the potential to increase celiprolol serum concentrations.<sup>2,3</sup> <br><br>In contrast, one study compared the combination of verapamil and celiprolol to the combination of verapamil and atenolol in 18 hypertensive patients and found that heart rate reduction and PR interval prolongation was greater in the verapamil/atenolol group compared with those in the verapamil/celiprolol group.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Celectol (celiprolol) [summary of product characteristics]. Surrey, United Kingdom: Winthrop Pharmaceuticals UK Limited; August 2014.</p>\n<p>2. Selectol (celiprolol) [KR product information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200001290. Accessed July 13, 2017.</p>\n<p>3. Lilja JJ, Backman JT, Laitila J, Luurila H, Neuvonen PJ. Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. <i>Clin Pharmacol Ther</i>. 2003;73(3):192-198. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12621384\">[PubMed 12621384]</a></p>\n<p>4. McInnes GT, McLenachan JM, Henderson E, Herrick AL, Dargie HJ. Celiprolol and verapamil in the treatment of essential hypertension. <i>Am Heart J</i>. 1988;116(5 pt 2):1437-1438. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2903656\">[PubMed 2903656]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11439":"<p><b>Title</b> Celiprolol / Mefloquine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Mefloquine may enhance the bradycardic effect of Celiprolol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased heart rate and bradycardia if celiprolol is combined with mefloquine.</p> \n<p><b>Discussion</b> Celiprolol product labeling states that because both mefloquine and celiprolol can cause bradycardia, their combined use should be done with caution.<sup>1,2</sup> Patients should be monitored for decreased heart rate and bradycardia when these agents are combined.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Celectol (celiprolol) [summary of product characteristics]. Surrey, United Kingdom: Winthrop Pharmaceuticals UK Limited; August 2014.</p>\n<p>2. Selectol (celiprolol) [KR product information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200001290. Accessed July 13, 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11440":"<p><b>Title</b> Celiprolol / Chlorthalidone</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Chlorthalidone may decrease the serum concentration of Celiprolol. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Celiprolol product labeling states that coadministration of chlorthalidone or hydrochlorthiazide with celiprolol reduces the bioavailability of celiprolol.<sup>1,2</sup> No published studies have evaluated the concomitant use of celiprolol with chlorthalidone or hydrochlorothiazide and no additional details are provided in product labeling.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Celectol (celiprolol) [summary of product characteristics]. Surrey, United Kingdom: Winthrop Pharmaceuticals UK Limited; August 2014.</p>\n<p>2. Selectol (celiprolol) [KR product information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200001290. Accessed July 13, 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11441":"<p><b>Title</b> Celiprolol / HydroCHLOROthiazide</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> HydroCHLOROthiazide may decrease the serum concentration of Celiprolol. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Celiprolol product labeling states that coadministration of chlorthalidone or hydrochlorthiazide with celiprolol reduces the bioavailability of celiprolol.<sup>1,2</sup> No published studies have evaluated the concomitant use of celiprolol with chlorthalidone or hydrochlorothiazide and no additional details are provided in product labeling.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Celectol (celiprolol) [summary of product characteristics]. Surrey, United Kingdom: Winthrop Pharmaceuticals UK Limited; August 2014.</p>\n<p>2. Selectol (celiprolol) [KR product information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200001290. Accessed July 13, 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11442":"<p><b>Title</b> Temsirolimus / Dexamethasone (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dexamethasone (Systemic) may decrease serum concentrations of the active metabolite(s) of Temsirolimus. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor serum concentrations of sirolimus (active metabolite) along with any indicators of temsirolimus effectiveness closely with any combined use of temsirolimus and dexamethasone. The temsirolimus labeling lists dexamethasone as an example of a strong CYP3A4 inducer, but available evidence indicates dexamethasone is only a weak inducer of CYP3A4, raising questions about whether the labeled recommendation should apply to dexamethasone. The labeling recommendation is to consider increasing the dose of temsirolimus to 50 mg IV/week (from 25 mg IV/week) if a concomitant CYP3A4 strong inducer is necessary. If the strong CYP3A4 inducer is discontinued, decrease temsirolimus to the dose used prior to the initiation of the CYP3A4 inducer.</p> \n<p><b>Discussion</b> The degree to which dexamethasone induces CYP3A4 is important to evaluation of this potential interaction. The temisirolimus labeling lists dexamethasone as an example of a strong CYP3A4 inducer,<sup>1</sup> but available published data shows dexamethasone to be only a weak CYP3A4 inducer. The AUC of two different CYP3A4 substrates were decreased by 14% to 19% with concurrent dexamethasone in two separate studies.<sup>2,3</sup> In another study, CYP3A activity, as estimated by the erythromycin breath test, was increased by approximately 25%.<sup>4</sup><br><br>The co-administration of temsirolimus and a strong CYP3A4 inducer is not recommended by the manufacturer.<sup>1</sup> However, if such an inducer is indicated, an increased dose of 50 mg IV/week (from 25 mg IV/week) of temsirolimus is warranted.<sup>1</sup> This dosage adjustment has not been clinically evaluated; rather, it is based on the extrapolation of pharmacokinetic data to predict temsirolimus and sirolimus pharmacokinerics without an interacting agent.<sup>1,5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Torisel (temsirolimus) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; May 2017.</p>\n<p>2. Stoch SA, Gargano C, Valentine J, et al. Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant. <i>Cancer Chemother Pharmacol</i>. 2011;67(6):1313-1321. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20734049\">[PubMed 20734049]</a></p>\n<p>3. Villikka K, Kivisto KT, Neuvonen PJ. The effect of dexamethasone on the pharmacokinetics of triazolam. <i>Pharmacol Toxicol</i>. 1998;83(3):135-138. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9783333\">[PubMed 9783333]</a></p>\n<p>4. McCune JS, Hawke RL, LeCluyse EL, et al. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. <i>Clin Pharmacol Ther</i>. 2000;68(4):356-366. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11061575\">[PubMed 11061575]</a></p>\n<p>5. Boni J, Leister C, Burns J, et al. Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome P450-inducing medications. <i>J Clin Pharmacol</i>. 2007;47:1430-1439. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17913896\">[PubMed 17913896]</a></p>\n<p>6. Zimmerman JJ. Exposure-response relationships and drug interactions of sirolimus. <i>AAPS J</i>. 2004;6(4):1-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15760093\">[PubMed 15760093]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11443":"<p><b>Title</b> Colchicine / Tacrolimus (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Tacrolimus (Systemic) may increase the serum concentration of Colchicine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patient closely for evidence of colchicine toxicity when used together with tacrolimus.</p> \n<p><b>Discussion</b> The colchicine AUC was an average of 3.2-fold higher among 6 patients with familial Mediterranean fever (FMF) who were also kidney transplant recipients and receiving tacrolimus (trough concentrations 5 ng/mL to 8 ng/mL), prednisolone, and mycophenolate mofetil as compared to 6 controls with FMF and normal renal function.<sup>1</sup> The post-transplant patients also had slightly decreased renal function as compared to control (estimated GFR was 34% lower), possibly explaining at least some of the observed difference, but the colchicine AUC was only an average of 1.5-fold higher among a group of 3 patients with FMF and impaired renal function (average estimated GFR = 25 mL/min) compared to controls, suggesting that other factors are contributing to this difference. The authors of this report attribute much of the observed difference to an interaction between colchicine and tacrolimus.<sup>1</sup> A published case report describes a 62-year-old patient who had been stable after a transplant and experienced suspected colchicine toxicity shortly after the addition of colchicine to a regimen that included tacrolimus.<sup>2</sup> An interaction between tacrolimus and colchicine was again implicated in the apparent interaction.<br><br>The specific mechanism for this possible interaction is unclear but has been attributed to inhibition of colchicine transport by p-glycoprotein and/or inhibition of colchicine metabolism by CYP3A4. While some in vitro data suggest tacrolimus may inhibit p-glycoprotein, this effect has not been confirmed in clinical studies. Similarly, there is no available clinical evidence to support that tacrolimus is a significant inhibitor of CYP3A4.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Amanova A, Kendi Celebi Z, Bakar F, Caglayan MG, Keven K. Colchicine levels in chronic kidney diseases and kidney transplant recipients using tacrolimus. <i>Clin Transplant</i>. 2014;28(10):1177-1183. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25125128\">[PubMed 25125128]</a></p>\n<p>2. Yousuf Bhat Z, Reddy S, Pillai U, Doshi M, Wilpula E. Colchicine-induced myopathy in a tacrolimus-treated renal transplant recipient: case report and literature review. <i>Am J Ther</i>. 2016;23(2):e614-616. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24732905\">[PubMed 24732905]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11444":"<p><b>Title</b> Selexipag / CYP2C8 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP2C8 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Selexipag. CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Selexipag. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> If initiating selexipag in a patient on a moderate CYP2C8 inhibitor, consider a less frequent dosing regimen (ie, once daily). If initiating a moderate CYP2C8 inhibitor in a patient on selexipag, consider a selexipag dose reduction. Monitor patients for increased selexipag effects/toxicities.</p>\n<div>\n <p><b>CYP2C8 Inhibitors (Moderate) Interacting Members</b> Clopidogrel, Deferasirox, Leflunomide, Teriflunomide</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 20 healthy volunteers, the strong CYP2C8 inhibitor gemfibrozil (600 mg twice daily on days 1 to 9) increased the selexipag (400 mcg single dose given on day 4) AUC and maximum serum concentration (Cmax) 2-fold and 1.4-fold, respectively.<sup>1</sup> The AUC and Cmax of the active metabolite ACT-333679 increased 11.1-fold and 3.6-fold in the presence of gemfibrozil.<sup>1</sup> Adverse events (eg, headache, nausea, vomiting) occurred more frequently with the combination of gemfibrozil and selexipag than with either drug alone.<sup>1</sup><br><br>Selexipag prescribing information states that although not studied, use of selexipag with moderate CYP2C8 inhibitors is expected to increase exposure to the active metabolite of selexipag.<sup>2</sup> Consider a less frequent dosing regimen (ie, once daily) when initiating selexipag in patients on a moderate CYP2C8 inhibitor and consider reducing the selexipag dose when a moderate CYP2C8 inhibitor is initiated in a patient on selexipag.<sup>2</sup><br><br>The suspected mechanism of this interaction is gemfibrozil-mediated inhibition of CYP2C8, an enzyme responsible for the metabolism of ACT333679.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bruderer S, Petersen-Sylla M, Boehler M, Remenova T, Halabi A, Dingemanse J. Effect of gemfibrozil or rifampin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects [published online July 17, 2017]. <i>Br J Clin Pharmacol</i>. doi: 10.1111/bcp.13379. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28715853\">[PubMed 28715853]</a> </p>\n<p>2. Uptravi (selexipag) [prescribing information]. South San Francisco, CA: Actelion Pharmaceutical US Inc; July 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11446":"<p><b>Title</b> Selexipag / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> RifAMPin may decrease serum concentrations of the active metabolite(s) of Selexipag. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Increase the selexipag dose (up to 2-fold) when combined with rifampin. Monitor for decreased selexipag efficacy.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 19 healthy volunteers, the strong CYP2C8 inducer rifampin (600 mg daily on days 1 to 9) actually increased the selexipag (400 mcg single dose given on day 7) AUC and maximum serum concentration 1.25-fold and 1.76-fold, respectively.<sup>1</sup> However, the AUC of the active metabolite ACT-333679 decreased 50%.<sup>1</sup><br><br>Selexipag prescribing information states that because rifampin induces CYP2C8, UGT1A3, and UGT2B7, exposure to ACT-333679 is significantly reduced when combined with selexipag.<sup>2</sup> The selexipag dose should be increased (up to 2-fold) when combined with rifampin.<sup>2</sup><br><br>The suspected mechanism of this interaction is rifampin-mediated induction of CYP2C8, UGT1A3, and UGT2B7, enzymes responsible for ACT-333678 metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bruderer S, Petersen-Sylla M, Boehler M, Remenova T, Halabi A, Dingemanse J. Effect of gemfibrozil or rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects [published online July 17, 2017]. <i>Br J Clin Pharmacol</i>. doi: 10.1111/bcp.13379. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28715853\">[PubMed 28715853]</a> </p>\n<p>2. Uptravi (selexipag) [prescribing information]. South San Francisco, CA: Actelion Pharmaceutical US Inc; July 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11447":"<p><b>Title</b> Mizolastine / Macrolide Antibiotics</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Macrolide Antibiotics may increase the serum concentration of Mizolastine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of mizolastine with macrolide antibiotics is listed as contraindicated.</p>\n<div>\n <p><b>Macrolide Antibiotics Interacting Members</b> Azithromycin (Systemic), Clarithromycin, Erythromycin (Systemic), Fidaxomicin, Roxithromycin, Spiramycin, Telithromycin</p>\n</div> \n<p><b>Discussion</b> Mizolastine concentrations with concurrent erythromycin (1 gram twice daily) were similar to what would be expected following a 15 mg or 20 mg mizolastine dose (despite a 10 mg dose being administered).<sup>1,2</sup><br><br>The specific mechanism for this apparent interaction is unclear as mizolastine appears primarily dependent on conjugation, with only minor dependence on oxidative metabolism. Erythromycin and other macrolides may inhibit the secondary oxidative metabolic processes, but it is unclear if they can significantly alter the conjugation of mizolastine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lebrun-Vignes B, Diquet B, Chosidow O. Clinical pharmacokinetics of mizolastine. <i>Clin Pharmacokinet</i>. 2001;40(7):501-507. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11510627\">[PubMed 11510627]</a></p>\n<p>2. Mizollen (mizolastine) [UK summary of product characteristics]. Guilford, Surrey, United Kingdom: Sanofi-aventis; December 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11448":"<p><b>Title</b> Mizolastine / Antifungal Agents (Azole Derivatives, Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Mizolastine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of mizolastine with systemic azole antifungal agents is listed as contraindicated.</p>\n<div>\n <p><b>Antifungal Agents (Azole Derivatives, Systemic) Interacting Members</b> Fluconazole, Isavuconazonium Sulfate, Itraconazole, Ketoconazole (Systemic), Posaconazole, Voriconazole</p>\n</div> \n<p><b>Discussion</b> Mizolastine concentrations with concurrent ketoconazole (100 mg, 200 mg, or 400 mg) were increased by as much as 2-fold from a study of 12 subjects.<sup>1,2</sup> The mizolastine beta half-life was not significantly changed.<br><br>The specific mechanism for this apparent interaction is unclear as mizolastine appears primarily dependent on conjugation, with only minor dependence on oxidative metabolism. Ketoconazole and other azole antifungal agents may inhibit the secondary oxidative metabolic processes, but it is unclear if they can significantly alter the conjugation of mizolastine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lebrun-Vignes B, Diquet B, Chosidow O. Clinical pharmacokinetics of mizolastine. <i>Clin Pharmacokinet</i>. 2001;40(7):501-507. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11510627\">[PubMed 11510627]</a></p>\n<p>2. Mizollen (mizolastine) [UK summary of product characteristics]. Guilford, Surrey, United Kingdom: Sanofi-aventis; December 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11449":"<p><b>Title</b> QTc-Prolonging Agents (Highest Risk) / Mizolastine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Mizolastine may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of mizolastine with higher risk QT-prolonging drugs is listed as contraindicated.</p>\n<div>\n <p><b>QTc-Prolonging Agents (Highest Risk) Interacting Members</b> Ajmaline, Amiodarone, Anagrelide, Arsenic Trioxide, Artemether, Asenapine, Astemizole, Bepridil, Cisapride, Citalopram, Deutetrabenazine, Disopyramide, Dofetilide, Domperidone, Dosulepin, Dronedarone, Eliglustat, FLUoxetine, Flupentixol, Halofantrine, Ibutilide, Iloperidone, Lopinavir, Lumefantrine, MiFEPRIStone, Nilotinib, Paliperidone, Pimavanserin, Pimozide, Pipamperone [INT], Procainamide, QUEtiapine, QuiNIDine, QuiNINE, Radotinib, Ribociclib, Sotalol, Sparfloxacin, Sulpiride, Terfenadine, Tetrabenazine, Thioridazine, Toremifene, Vandetanib, Vemurafenib, Vernakalant, Ziprasidone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> The mizolastine labeling describes mizolastine as both having a weak potential to prolong the QT interval and causing modest QT prolongation.<sup>1</sup> Specific data are not included in the label. In contrast, no significant QT prolongation was noted with therapeutic or supratherapeutic mizolastine doses (including both single-dose and multiple-dose) in two separate studies.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mizollen (mizolastine) [UK summary of product characteristics]. Guilford, Surrey, United Kingdom: Sanofi-aventis; December 2014.</p>\n<p>2. Delauche-Cavallier MC, Chaufour S, Guerault E, Lacroux A, Murrieta M, Wajman A. QT interval monitoring during clinical studies with mizolastine, a new H1 antihistamine. <i>Clin Exp Allergy</i>. 1999;29 Suppl 3:206-211. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10444239\">[PubMed 10444239]</a></p>\n<p>3. Chaufour S, Caplain H, Lilienthal N, et al. Study of cardiac repolarization in healthy volunteers performed with mizolastine, a new H1-receptor antagonist. <i>Br J Clin Pharmacol</i>. 1999;47(5):515-520. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10336575\">[PubMed 10336575]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11458":"<p><b>Title</b> Gemigliptin / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Gemigliptin. CYP3A4 Inducers (Strong) may decrease the serum concentration of Gemigliptin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concomitant use of gemigliptin and strong CYP3A4 inducers is not recommended.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 11 healthy volunteers, rifampin (600 mg daily for 10 days) decreased the gemigliptin (50 mg single dose) maximum serum concentration and AUC 59% and 80%, respectively.<sup>1</sup> The AUC of LC15-0636 (the active metabolite with an activity that is 2-fold greater than the parent drug gemigliptin) decreased 40% and the net exposure to the active moiety (a combination of gemigliptin and LC15-0636) decreased 70% during coadministration with ketoconazole.<sup>1</sup><br><br>Gemigliptin product labeling states that because coadministration with rifampin caused a clinically meaningful decrease in gemigliptin and LC15-0636 exposure, concomitant use with strong CYP3A4 inducers is not recommended.<sup>2</sup><br><br>The mechanism of this interaction is likely rifampin-mediated induction of CYP3A4, an enzyme responsible for gemigliptin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Noh YH, Lim HS, Jin SJ, et al. Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers. <i>Clin Ther</i>. 2012;34(5):1182-1194. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22534255\">[PubMed 22534255]</a></p>\n<p>2. Zemiglo (gemigliptin tartrate sesquihydrate) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=201205933. Accessed June 5, 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11459":"<p><b>Title</b> Gemigliptin / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Gemigliptin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 healthy volunteers, ketoconazole (400 mg orally daily for 7 days) increased the gemigliptin (50 mg single dose) maximum serum concentration and AUC approximately 2.4-fold.<sup>1</sup> Concentrations of LC15-0636 (the active metabolite with an activity that is 2-fold greater than the parent drug gemigliptin) were undetectable during coadministration with ketoconazole.<sup>1</sup> The net exposure to the active moiety (a combination of gemigliptin and LC15-0636) was increased 1.9-fold during ketoconazole therapy.<sup>1</sup><br><br>Gemigliptin product labeling states that the increase in exposure to the active moiety is unlikely to be clinically significant and gemigliptin can be combined with strong CYP3A4 inhibitors.<sup>2</sup><br><br>The mechanism of this interaction is likely ketoconazole-mediated inhibition of CYP3A4, an enzyme responsible for gemigliptin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Noh YH, Lim HS, Jin SJ, et al. Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers. <i>Clin Ther</i>. 2012;34(5):1182-1194. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22534255\">[PubMed 22534255]</a></p>\n<p>2. Zemiglo (gemigliptin tartrate sesquihydrate) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=201205933. Accessed June 5, 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11460":"<p><b>Title</b> Perampanel / CYP3A4 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may decrease the serum concentration of Perampanel. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> An increase in the perampanel starting dose to 4 mg/day is recommended when perampanel is used in combination with moderate and strong CYP3A4 inducers. Patients receiving such combinations should be followed closely for response, particularly with any changes to CYP3A4 inducer therapy (ie, starting, stopping, dose changes).</p>\n<div>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n</div> \n<p><b>Discussion</b> The perampanel AUC was reduced by an average of 67% in a study of healthy individuals who received carbamazepine (300 mg twice daily) prior to a single dose of perampanel (2 mg).<sup>1</sup> Similarly, according to a population pharmacokinetic analysis based on clinical studies of perampanel, carbamazepine use was associated with an average 64% reduction in perampanel AUC as compared with patients not receiving concomitant enzyme-inducing antiepileptic drugs.<sup>1</sup> In other similar pharmacokinetic analyses, the concurrent use of oxcarbazepine and phenytoin were each associated with an average 50% reduction in perampanel AUC.<sup>1</sup> Concurrent use of topiramate, a weak to moderate enzyme inducer, was also associated with an average 20% reduction in perampanel AUC. In contrast, limited data with phenobarbital and the related agent primidone (n = 37 and n = 9, respectively), demonstrated no significant change in perampanel concentrations, despite phenobarbital's classification as a strong CYP3A4 inducer.<sup>1</sup><br><br>Based on these findings, the perampanel prescribing information recommends using a higher perampanel starting dose when used together with moderate and strong CYP3A4 inducers.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Fycompa (perampanel) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; July 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11461":"<p><b>Title</b> Ibrutinib / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Ibrutinib. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Patients should avoid consumption of grapefruit or grapefruit juice while taking ibrutinib.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 8 healthy volunteers, the pharmacokinetics of ibrutinib (560 mg single dose) were compared with the pharmacokinetics of ibrutinib (140 mg single dose) combined with the moderate CYP3A4 inhibitor grapefruit juice (240 mL single dose).<sup>1</sup> The dose-normalized ibrutinib maximum serum concentration (Cmax) and AUC increased 3.5-fold and 2.2-fold, respectively.<sup>1</sup><br><br>Ibrutinib prescribing information states that because grapefruit juice can increase exposure to ibrutinib, patients should avoid grapefruit during treatment with ibrutinib.<sup>2</sup><br><br>The mechanism of this interaction is grapefruit juice-mediated inhibition of intestinal CYP3A4, an enzyme responsible for ibrutinib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. de Jong J, Skee D, Murphy J, et al. Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants. <i>Pharmacol Res Perspect</i>. 2015;3(4):e00156. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26171235\">[PubMed 26171235]</a></p>\n<p>2. Imbruvica (ibrutinib) [prescribing information]. Horsham, PA: Janssen Biotech Inc; August 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11462":"<p><b>Title</b> Ibrutinib / Posaconazole</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: The management of this interaction differs based on the dose of posaconazole.</p></li>\n <li><p><b>Indication</b>: The management of this interaction differs when ibrutinib is used for the treatment of B-cell malignancies versus when ibrutinib is used for the treatment of graft versus host disease.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Posaconazole may increase the serum concentration of Ibrutinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> When ibrutinib is used for the treatment of B-cell malignancies, decrease the ibrutinib dose to 140 mg daily when combined with posaconazole suspension at doses of 100 mg<br>once daily, 100 mg twice daily, or 200 mg twice daily. Decrease the ibrutinib dose to 70 mg daily when combined with posaconazole suspension at doses of 200 mg three times daily or 400 mg twice daily, IV posaconazole 300 mg daily, or posaconazole delayed-release tablets 300 mg once daily.<br><br>When ibrutinib is used for the treatment of graft versus host disease, decrease the ibrutinib dose to 280 mg daily when combined with posaconazole suspension at doses of 100 mg<br>once daily, 100 mg twice daily, or 200 mg twice daily. Decrease the ibrutinib dose to 140 mg daily when combined with posaconazole suspension at doses of 200 mg three times daily or 400 mg twice daily, IV posaconazole 300 mg daily, or posaconazole delayed-release tablets 300 mg once daily.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 18 healthy volunteers, the pharmacokinetics of ibrutinib (120 mg single dose) were compared with the pharmacokinetics of ibrutinib (40 mg single dose) combined with the strong CYP3A4 inhibitor ketoconazole (400 mg daily for 6 days).<sup>1</sup> The dose-normalized ibrutinib maximum serum concentration (Cmax) and AUC increased 29-fold and 24-fold, respectively, with coadministration of ketoconazole.<sup>1</sup> Ibrutinib prescribing information describes another pharmacokinetic study where voriconazole increased ibrutinib Cmax and AUC 6.7-fold and 5.7-fold, respectively.<sup>2</sup> Additionally, simulations under fed conditions suggest that posaconazole may increase the ibrutinib AUC 7- to 10-fold.<sup>2</sup><br><br>Ibrutinib prescribing information states that concomitant use of ibrutinib and strong CYP3A4 inhibitors should be avoided, but allows for ibrutinib dose reductions when combined with posaconazole.<sup>2</sup><br><br>The mechanism of this interaction is likely inhibition of CYP3A4, an enzyme responsible for ibrutinib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. de Jong J, Skee D, Murphy J, et al. Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants. <i>Pharmacol Res Perspect</i>. 2015;3(4):e00156. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26171235\">[PubMed 26171235]</a></p>\n<p>2. Imbruvica (ibrutinib) [prescribing information]. Horsham, PA: Janssen Biotech Inc; December 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11463":"<p><b>Title</b> Ibrutinib / Voriconazole</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: The management of this interaction differs based on the dose of voriconazole.</p></li>\n <li><p><b>Indication</b>: The management of this interaction differs when ibrutinib is used for the treatment of B-cell malignancies versus when ibrutinib is used for the treatment of graft versus host disease.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Voriconazole may increase the serum concentration of Ibrutinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> When ibrutinib is used for the treatment of B-cell malignancies, decrease the ibrutinib dose to 140 mg daily when combined with voriconazole 200 mg twice daily. Recommendations for use with higher doses of voriconazole are not provided, but because use with other strong CYP3A4 inhibitors should be avoided, avoidance of higher doses of voriconazole may be warranted.<br><br>When ibrutinib is used for the treatment of graft versus host disease, decrease the ibrutinib dose to 280 mg daily when combined with voriconazole 200 mg twice daily. Recommendations for use with higher doses of voriconazole are not provided, but because use with other strong CYP3A4 inhibitors should be avoided, avoidance of higher doses of voriconazole may be warranted.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the ibrutinib prescribing information, voriconazole increased the ibrutinib maximum serum concentration and AUC 6.7-fold and 5.7-fold, respectively.<sup>1</sup> <br><br>Ibrutinib prescribing information states that when ibrutinib is used for the treatment of B-cell malignancies, the ibrutinib dose should be decreased to 140 mg daily when combined with voriconazole 200 mg twice daily.<sup>1</sup> When ibrutinib is used for the treatment of graft versus host disease, the ibrutinib dose should be decreased to 280 mg daily when combined with voriconazole 200 mg twice daily.<sup>1</sup> Recommendations for use with higher doses of voriconazole are not provided, but because use with other strong CYP3A4 inhibitors should be avoided, avoidance of higher doses of voriconazole may be warranted.<sup>1</sup><br><br>The mechanism of this interaction is likely due to voriconazole-mediated inhibition of CYP3A4, an enzyme responsible for ibrutinib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Imbruvica (ibrutinib) [prescribing information]. Horsham, PA: Janssen Biotech Inc; December 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11464":"<p><b>Title</b> Ibrutinib / DilTIAZem</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> DilTIAZem may increase the serum concentration of Ibrutinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of ibrutinib and diltiazem. If diltiazem must be used short-term (for 7 days or less), interrupt ibrutinib therapy until diltiazem has been discontinued.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 18 healthy volunteers, the pharmacokinetics of ibrutinib (120 mg single dose) were compared with the pharmacokinetics of ibrutinib (40 mg single dose) combined with the strong CYP3A4 inhibitor ketoconazole (400 mg daily for 6 days).<sup>1</sup> The dose-normalized ibrutinib maximum serum concentration (Cmax) and AUC increased 29-fold and 24-fold, respectively, with coadministration of ketoconazole.<sup>1</sup> Ibrutinib prescribing information describes another pharmacokinetic study where voriconazole increased ibrutinib Cmax and AUC 6.7-fold and 5.7-fold, respectively, and simulations under fed conditions suggest that posaconazole may increase the ibrutinib AUC 7- to 10-fold.<sup>2</sup> A physiologically based pharmacokinetic modeling study predicted a 4.7-fold and 4.9-fold increase in ibrutinib Cmax and AUC, respectively, when combined with diltiazem.<sup>3</sup><br><br>Ibrutinib prescribing information states that concomitant use of ibrutinib and strong CYP3A4 inhibitors should be avoided.<sup>2</sup> If a strong CYP3A4 inhibitor is need for short-term therapy (ie, anti-infectives for 7 days or less), ibrutinib therapy should be interrupted until the strong CYP3A4 inhibitor is discontinued.<sup>2</sup> Although diltiazem is listed as an example of a strong CYP3A4 inhibitor in the ibrutinib prescribing information, the majority of clinical data suggests it is a moderate CYP3A4 inhibitor.<sup>4,5,6</sup><br><br>The mechanism of this interaction is likely inhibition of CYP3A4, an enzyme responsible for ibrutinib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. de Jong J, Skee D, Murphy J, et al. Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants. <i>Pharmacol Res Perspect</i>. 2015;3(4):e00156. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26171235\">[PubMed 26171235]</a></p>\n<p>2. Imbruvica (ibrutinib) [prescribing information]. Horsham, PA: Janssen Biotech Inc; August 2017.</p>\n<p>3. de Zwart L, Snoeys J, De Jong J, Sukbuntherng J, Mannaert E, Monshouwer M. Ibrutinib dosing strategies based on interaction potential of CYP3A4 perpetrators using physiologically based pharmacokinetic modeling. <i>Clin Pharmacol Ther</i>. 2016;100(5):548-557. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27367453\">[PubMed 27367453]</a></p>\n<p>4. Varhe A, Olkkola KT, Neuvonen PJ. Diltiazem enhances the effects of triazolam by inhibiting its metabolism. <i>Clin Pharmacol Ther</i>. 1996;59(4):369-375. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8612379\">[PubMed 8612379]</a></p>\n<p>5. Backman JT, Olkkola KT, Aranko K, Himberg JJ, Neuvonen P. Dose of midazolam should be reduced during diltiazem and verapamil treatments. <i>Br J Clin Pharmacol</i>. 1994;37(3):221-225. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8198928\">[PubMed 8198928]</a></p>\n<p>6. Cardizem (diltiazem) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; November 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11465":"<p><b>Title</b> Ibrutinib / Conivaptan</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Conivaptan may increase the serum concentration of Ibrutinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of ibrutinib and conivaptan. If conivaptan must be used short-term (for 7 days or less), interrupt ibrutinib therapy until conivaptan has been discontinued.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 18 healthy volunteers, the pharmacokinetics of ibrutinib (120 mg single dose) were compared with the pharmacokinetics of ibrutinib (40 mg single dose) combined with the strong CYP3A4 inhibitor ketoconazole (400 mg daily for 6 days).<sup>1</sup> The dose-normalized ibrutinib maximum serum concentration (Cmax) and AUC increased 29-fold and 24-fold, respectively, with coadministration of ketoconazole.<sup>1</sup> Ibrutinib prescribing information describes another pharmacokinetic study where voriconazole increased ibrutinib Cmax and AUC 6.7-fold and 5.7-fold, respectively.<sup>2</sup> Additionally, simulations under fed conditions suggest that posaconazole may increase the ibrutinib AUC 7- to 10-fold.<sup>2</sup><br><br>Ibrutinib prescribing information states that concomitant use of ibrutinib and strong CYP3A4 inhibitors should be avoided.<sup>2</sup> If a strong CYP3A4 inhibitor is need for short-term therapy (ie, anti-infectives for 7 days or less), ibrutinib therapy should be interrupted until the strong CYP3A4 inhibitor is discontinued.<sup>2</sup> Although conivaptan is listed as an example of a strong CYP3A4 inhibitor in the ibrutinib prescribing information, the majority of clinical data suggests it is a moderate CYP3A4 inhibitor.<sup>3</sup><br><br><br>The mechanism of this interaction is likely inhibition of CYP3A4, an enzyme responsible for ibrutinib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. de Jong J, Skee D, Murphy J, et al. Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants. <i>Pharmacol Res Perspect</i>. 2015;3(4):e00156. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26171235\">[PubMed 26171235]</a></p>\n<p>2. Imbruvica (ibrutinib) [prescribing information]. Horsham, PA: Janssen Biotech Inc; August 2017.</p>\n<p>3. Vaprisol (conivaptan) [prescribing information]. Nashville TN: Cumberland Pharmaceuticals Inc; October 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11466":"<p><b>Title</b> Ibrutinib / Cimetidine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: The management of this interaction differs when ibrutinib is used for the treatment of B-cell malignancies versus when ibrutinib is used for the treatment of graft versus host disease.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Ibrutinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> When ibrutinib is used for the treatment of B-cell malignancies, consider decreasing the ibrutinib dose to 140 mg daily when combined cimetidine.<br><br>When ibrutinib is used for the treatment of graft versus host disease, no preemptive dose reduction is recommended when combined with cimetidine. Patients should be monitored closely for ibrutinib toxicities and ibrutinib dose reductions should occur as needed based on adverse reactions.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 8 healthy volunteers, the pharmacokinetics of ibrutinib (560 mg single dose) were compared with the pharmacokinetics of ibrutinib (140 mg single dose) combined with the moderate CYP3A4 inhibitor grapefruit juice (240 mL single dose).<sup>1</sup> The dose-normalized ibrutinib maximum serum concentration (Cmax) and AUC increased 3.5-fold and 2.2-fold, respectively.<sup>1</sup> In a separate pharmacokinetic study described in the ibrutinib prescribing information, multiple doses of erythromycin (to achieve steady state) increased the ibrutinib Cmax and AUC 3.4-fold and 3-fold, respectively.<sup>2</sup><br><br>Ibrutinib prescribing information states that when ibrutinib is used for the treatment of B-cell malignancies, the ibrutinib dose should be decreased to 140 mg daily when combined with moderate CYP3A4 inhibitors.<sup>2</sup> When ibrutinib is used for the treatment of graft versus host disease, no preemptive dose reduction is recommended when combined with moderate CYP3A4 inhibitors, but patients should be monitored closely for ibrutinib toxicities and ibrutinib dose reductions should occur as needed based on adverse reactions.<sup>2</sup> Although ibrutinib product labeling lists cimetidine, ciprofloxacin, clotrimazole, cyclosporine, fluvoxamine, and tofisopam as examples of moderate CYP3A4 inhibitors,<sup>2</sup> the majority of clinical data suggests that these agents are more often classified as weak CYP3A4 inhibitors.<sup>3,4,5,6,7,8,9,10,11</sup><br><br>The mechanism of this interaction is likely due to inhibition of CYP3A4, an enzyme responsible for ibrutinib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. de Jong J, Skee D, Murphy J, et al. Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants. <i>Pharmacol Res Perspect</i>. 2015;3(4):e00156. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26171235\">[PubMed 26171235]</a></p>\n<p>2. Imbruvica (ibrutinib) [prescribing information]. Horsham, PA: Janssen Biotech Inc; August 2017.</p>\n<p>3. Martinez C, Albet C, Aqundez JA, et al. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. <i>Clin Pharmacol Ther</i>. 1999;65(4):369-376. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10223772\">[PubMed 10223772]</a></p>\n<p>4. Friedman H, Greenblatt DJ, Burstein ES, Scavone JM, Harmatz JS, Shader RI. Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. <i>J Clin Pharmacol</i>. 1988;28(3):228-233. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3360971\">[PubMed 3360971]</a></p>\n<p>5. Sriwiriyajan S, Samaeng M, Ridtitid W, Mahatthanatrakul W, Wongnawa M. Pharmacokinetic interactions between ciprofloxacin and itraconazole in healthy male volunteers. <i>Biopharm Drug Dispos</i>. 2011;32(3):168-174. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21360715\">[PubMed 21360715]</a></p>\n<p>6. Shahzadi A, Javed I, Aslam B, et al. Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers. <i>Pak J Pharm Sci</i>. 2011;24(1):63-68. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21190921\">[PubMed 21190921]</a></p>\n<p>7. Shord SS, Chan LN, Camp JR, et al. Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam. <i>Br J Clin Pharmacol</i>. 2010;69(2):160-166. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20233179\">[PubMed 20233179]</a></p>\n<p>8. Madsen JK, Jensen JD, Jensen LW, Pedersen EB. Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine. <i>Eur J Clin Pharmacol</i>. 1996;50(3):203-208. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8737760\">[PubMed 8737760]</a></p>\n<p>9. Lam YW, Alfaro CL, Ereshefsky L, Miller M. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. <i>J Clin Pharmacol</i>. 2003;43(11):1274-1282. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14551182\">[PubMed 14551182]</a></p>\n<p>10. Kashuba AD, Nafziger AN, Kearns GL, et al. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. <i>Clin Pharmacol Ther</i>. 1998;64(3):257-268. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9757149\">[PubMed 9757149]</a></p>\n<p>11. Drabant S, Toth M, Bereczki A, Bajnogel J, Tomlo J, Klebovich I. Effect of tofisopam on the single-oral-dose pharmacokinetics and pharmacodynamics of the cyp3a4 probe drug alprazolam. <i>Eur J Clin Pharmacol</i>. 2006;62(7):587-588. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16791582\">[PubMed 16791582]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11467":"<p><b>Title</b> Ibrutinib / CycloSPORINE (Systemic)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: The management of this interaction differs when ibrutinib is used for the treatment of B-cell malignancies versus when ibrutinib is used for the treatment of graft versus host disease.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may increase the serum concentration of Ibrutinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> When ibrutinib is used for the treatment of B-cell malignancies, consider decreasing the ibrutinib dose to 140 mg daily when combined cyclosporine.<br><br>When ibrutinib is used for the treatment of graft versus host disease, no preemptive dose reduction is recommended when combined with cyclosporine. Patients should be monitored closely for ibrutinib toxicities and ibrutinib dose reductions should occur as needed based on adverse reactions.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 8 healthy volunteers, the pharmacokinetics of ibrutinib (560 mg single dose) were compared with the pharmacokinetics of ibrutinib (140 mg single dose) combined with the moderate CYP3A4 inhibitor grapefruit juice (240 mL single dose).<sup>1</sup> The dose-normalized ibrutinib maximum serum concentration (Cmax) and AUC increased 3.5-fold and 2.2-fold, respectively.<sup>1</sup> In a separate pharmacokinetic study described in the ibrutinib prescribing information, multiple doses of erythromycin (to achieve steady state) increased the ibrutinib Cmax and AUC 3.4-fold and 3-fold, respectively.<sup>2</sup><br><br>Ibrutinib prescribing information states that when ibrutinib is used for the treatment of B-cell malignancies, the ibrutinib dose should be decreased to 140 mg daily when combined with moderate CYP3A4 inhibitors.<sup>2</sup> When ibrutinib is used for the treatment of graft versus host disease, no preemptive dose reduction is recommended when combined with moderate CYP3A4 inhibitors, but patients should be monitored closely for ibrutinib toxicities and ibrutinib dose reductions should occur as needed based on adverse reactions.<sup>2</sup> Although ibrutinib product labeling lists cimetidine, ciprofloxacin, clotrimazole, cyclosporine, fluvoxamine, and tofisopam as examples of moderate CYP3A4 inhibitors,<sup>2</sup> the majority of clinical data suggests that these agents are more often classified as weak CYP3A4 inhibitors.<sup>3,4,5,6,7,8,9,10,11</sup><br><br>The mechanism of this interaction is likely due to inhibition of CYP3A4, an enzyme responsible for ibrutinib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. de Jong J, Skee D, Murphy J, et al. Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants. <i>Pharmacol Res Perspect</i>. 2015;3(4):e00156. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26171235\">[PubMed 26171235]</a></p>\n<p>2. Imbruvica (ibrutinib) [prescribing information]. Horsham, PA: Janssen Biotech Inc; August 2017.</p>\n<p>3. Martinez C, Albet C, Aqundez JA, et al. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. <i>Clin Pharmacol Ther</i>. 1999;65(4):369-376. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10223772\">[PubMed 10223772]</a></p>\n<p>4. Friedman H, Greenblatt DJ, Burstein ES, Scavone JM, Harmatz JS, Shader RI. Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. <i>J Clin Pharmacol</i>. 1988;28(3):228-233. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3360971\">[PubMed 3360971]</a></p>\n<p>5. Sriwiriyajan S, Samaeng M, Ridtitid W, Mahatthanatrakul W, Wongnawa M. Pharmacokinetic interactions between ciprofloxacin and itraconazole in healthy male volunteers. <i>Biopharm Drug Dispos</i>. 2011;32(3):168-174. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21360715\">[PubMed 21360715]</a></p>\n<p>6. Shahzadi A, Javed I, Aslam B, et al. Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers. <i>Pak J Pharm Sci</i>. 2011;24(1):63-68. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21190921\">[PubMed 21190921]</a></p>\n<p>7. Shord SS, Chan LN, Camp JR, et al. Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam. <i>Br J Clin Pharmacol</i>. 2010;69(2):160-166. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20233179\">[PubMed 20233179]</a></p>\n<p>8. Madsen JK, Jensen JD, Jensen LW, Pedersen EB. Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine. <i>Eur J Clin Pharmacol</i>. 1996;50(3):203-208. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8737760\">[PubMed 8737760]</a></p>\n<p>9. Lam YW, Alfaro CL, Ereshefsky L, Miller M. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. <i>J Clin Pharmacol</i>. 2003;43(11):1274-1282. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14551182\">[PubMed 14551182]</a></p>\n<p>10. Kashuba AD, Nafziger AN, Kearns GL, et al. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. <i>Clin Pharmacol Ther</i>. 1998;64(3):257-268. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9757149\">[PubMed 9757149]</a></p>\n<p>11. Drabant S, Toth M, Bereczki A, Bajnogel J, Tomlo J, Klebovich I. Effect of tofisopam on the single-oral-dose pharmacokinetics and pharmacodynamics of the cyp3a4 probe drug alprazolam. <i>Eur J Clin Pharmacol</i>. 2006;62(7):587-588. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16791582\">[PubMed 16791582]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11468":"<p><b>Title</b> Ibrutinib / FluvoxaMINE</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: The management of this interaction differs when ibrutinib is used for the treatment of B-cell malignancies versus when ibrutinib is used for the treatment of graft versus host disease.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> FluvoxaMINE may increase the serum concentration of Ibrutinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> When ibrutinib is used for the treatment of B-cell malignancies, consider decreasing the ibrutinib dose to 140 mg daily when combined fluvoxamine.<br><br>When ibrutinib is used for the treatment of graft versus host disease, no preemptive dose reduction is recommended when combined with fluvoxamine. Patients should be monitored closely for ibrutinib toxicities and ibrutinib dose reductions should occur as needed based on adverse reactions.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 8 healthy volunteers, the pharmacokinetics of ibrutinib (560 mg single dose) were compared with the pharmacokinetics of ibrutinib (140 mg single dose) combined with the moderate CYP3A4 inhibitor grapefruit juice (240 mL single dose).<sup>1</sup> The dose-normalized ibrutinib maximum serum concentration (Cmax) and AUC increased 3.5-fold and 2.2-fold, respectively.<sup>1</sup> In a separate pharmacokinetic study described in the ibrutinib prescribing information, multiple doses of erythromycin (to achieve steady state) increased the ibrutinib Cmax and AUC 3.4-fold and 3-fold, respectively.<sup>2</sup><br><br>Ibrutinib prescribing information states that when ibrutinib is used for the treatment of B-cell malignancies, the ibrutinib dose should be decreased to 140 mg daily when combined with moderate CYP3A4 inhibitors.<sup>2</sup> When ibrutinib is used for the treatment of graft versus host disease, no preemptive dose reduction is recommended when combined with moderate CYP3A4 inhibitors, but patients should be monitored closely for ibrutinib toxicities and ibrutinib dose reductions should occur as needed based on adverse reactions.<sup>2</sup> Although ibrutinib product labeling lists cimetidine, ciprofloxacin, clotrimazole, cyclosporine, fluvoxamine, and tofisopam as examples of moderate CYP3A4 inhibitors,<sup>2</sup> the majority of clinical data suggests that these agents are more often classified as weak CYP3A4 inhibitors.<sup>3,4,5,6,7,8,9,10,11</sup><br><br>The mechanism of this interaction is likely due to inhibition of CYP3A4, an enzyme responsible for ibrutinib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. de Jong J, Skee D, Murphy J, et al. Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants. <i>Pharmacol Res Perspect</i>. 2015;3(4):e00156. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26171235\">[PubMed 26171235]</a></p>\n<p>2. Imbruvica (ibrutinib) [prescribing information]. Horsham, PA: Janssen Biotech Inc; August 2017.</p>\n<p>3. Martinez C, Albet C, Aqundez JA, et al. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. <i>Clin Pharmacol Ther</i>. 1999;65(4):369-376. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10223772\">[PubMed 10223772]</a></p>\n<p>4. Friedman H, Greenblatt DJ, Burstein ES, Scavone JM, Harmatz JS, Shader RI. Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. <i>J Clin Pharmacol</i>. 1988;28(3):228-233. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3360971\">[PubMed 3360971]</a></p>\n<p>5. Sriwiriyajan S, Samaeng M, Ridtitid W, Mahatthanatrakul W, Wongnawa M. Pharmacokinetic interactions between ciprofloxacin and itraconazole in healthy male volunteers. <i>Biopharm Drug Dispos</i>. 2011;32(3):168-174. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21360715\">[PubMed 21360715]</a></p>\n<p>6. Shahzadi A, Javed I, Aslam B, et al. Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers. <i>Pak J Pharm Sci</i>. 2011;24(1):63-68. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21190921\">[PubMed 21190921]</a></p>\n<p>7. Shord SS, Chan LN, Camp JR, et al. Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam. <i>Br J Clin Pharmacol</i>. 2010;69(2):160-166. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20233179\">[PubMed 20233179]</a></p>\n<p>8. Madsen JK, Jensen JD, Jensen LW, Pedersen EB. Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine. <i>Eur J Clin Pharmacol</i>. 1996;50(3):203-208. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8737760\">[PubMed 8737760]</a></p>\n<p>9. Lam YW, Alfaro CL, Ereshefsky L, Miller M. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. <i>J Clin Pharmacol</i>. 2003;43(11):1274-1282. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14551182\">[PubMed 14551182]</a></p>\n<p>10. Kashuba AD, Nafziger AN, Kearns GL, et al. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. <i>Clin Pharmacol Ther</i>. 1998;64(3):257-268. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9757149\">[PubMed 9757149]</a></p>\n<p>11. Drabant S, Toth M, Bereczki A, Bajnogel J, Tomlo J, Klebovich I. Effect of tofisopam on the single-oral-dose pharmacokinetics and pharmacodynamics of the cyp3a4 probe drug alprazolam. <i>Eur J Clin Pharmacol</i>. 2006;62(7):587-588. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16791582\">[PubMed 16791582]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11469":"<p><b>Title</b> Ibrutinib / Tofisopam</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: The management of this interaction differs when ibrutinib is used for the treatment of B-cell malignancies versus when ibrutinib is used for the treatment of graft versus host disease.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Tofisopam may increase the serum concentration of Ibrutinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> When ibrutinib is used for the treatment of B-cell malignancies, consider decreasing the ibrutinib dose to 140 mg daily when combined tofisopam.<br><br>When ibrutinib is used for the treatment of graft versus host disease, no preemptive dose reduction is recommended when combined with tofisopam. Patients should be monitored closely for ibrutinib toxicities and ibrutinib dose reductions should occur as needed based on adverse reactions.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 8 healthy volunteers, the pharmacokinetics of ibrutinib (560 mg single dose) were compared with the pharmacokinetics of ibrutinib (140 mg single dose) combined with the moderate CYP3A4 inhibitor grapefruit juice (240 mL single dose).<sup>1</sup> The dose-normalized ibrutinib maximum serum concentration (Cmax) and AUC increased 3.5-fold and 2.2-fold, respectively.<sup>1</sup> In a separate pharmacokinetic study described in the ibrutinib prescribing information, multiple doses of erythromycin (to achieve steady state) increased the ibrutinib Cmax and AUC 3.4-fold and 3-fold, respectively.<sup>2</sup><br><br>Ibrutinib prescribing information states that when ibrutinib is used for the treatment of B-cell malignancies, the ibrutinib dose should be decreased to 140 mg daily when combined with moderate CYP3A4 inhibitors.<sup>2</sup> When ibrutinib is used for the treatment of graft versus host disease, no preemptive dose reduction is recommended when combined with moderate CYP3A4 inhibitors, but patients should be monitored closely for ibrutinib toxicities and ibrutinib dose reductions should occur as needed based on adverse reactions.<sup>2</sup> Although ibrutinib product labeling lists cimetidine, ciprofloxacin, clotrimazole, cyclosporine, fluvoxamine, and tofisopam as examples of moderate CYP3A4 inhibitors,<sup>2</sup> the majority of clinical data suggests that these agents are more often classified as weak CYP3A4 inhibitors.<sup>3,4,5,6,7,8,9,10,11</sup><br><br>The mechanism of this interaction is likely due to inhibition of CYP3A4, an enzyme responsible for ibrutinib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. de Jong J, Skee D, Murphy J, et al. Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants. <i>Pharmacol Res Perspect</i>. 2015;3(4):e00156. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26171235\">[PubMed 26171235]</a></p>\n<p>2. Imbruvica (ibrutinib) [prescribing information]. Horsham, PA: Janssen Biotech Inc; August 2017.</p>\n<p>3. Martinez C, Albet C, Aqundez JA, et al. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. <i>Clin Pharmacol Ther</i>. 1999;65(4):369-376. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10223772\">[PubMed 10223772]</a></p>\n<p>4. Friedman H, Greenblatt DJ, Burstein ES, Scavone JM, Harmatz JS, Shader RI. Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. <i>J Clin Pharmacol</i>. 1988;28(3):228-233. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3360971\">[PubMed 3360971]</a></p>\n<p>5. Sriwiriyajan S, Samaeng M, Ridtitid W, Mahatthanatrakul W, Wongnawa M. Pharmacokinetic interactions between ciprofloxacin and itraconazole in healthy male volunteers. <i>Biopharm Drug Dispos</i>. 2011;32(3):168-174. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21360715\">[PubMed 21360715]</a></p>\n<p>6. Shahzadi A, Javed I, Aslam B, et al. Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers. <i>Pak J Pharm Sci</i>. 2011;24(1):63-68. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21190921\">[PubMed 21190921]</a></p>\n<p>7. Shord SS, Chan LN, Camp JR, et al. Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam. <i>Br J Clin Pharmacol</i>. 2010;69(2):160-166. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20233179\">[PubMed 20233179]</a></p>\n<p>8. Madsen JK, Jensen JD, Jensen LW, Pedersen EB. Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine. <i>Eur J Clin Pharmacol</i>. 1996;50(3):203-208. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8737760\">[PubMed 8737760]</a></p>\n<p>9. Lam YW, Alfaro CL, Ereshefsky L, Miller M. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. <i>J Clin Pharmacol</i>. 2003;43(11):1274-1282. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14551182\">[PubMed 14551182]</a></p>\n<p>10. Kashuba AD, Nafziger AN, Kearns GL, et al. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. <i>Clin Pharmacol Ther</i>. 1998;64(3):257-268. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9757149\">[PubMed 9757149]</a></p>\n<p>11. Drabant S, Toth M, Bereczki A, Bajnogel J, Tomlo J, Klebovich I. Effect of tofisopam on the single-oral-dose pharmacokinetics and pharmacodynamics of the cyp3a4 probe drug alprazolam. <i>Eur J Clin Pharmacol</i>. 2006;62(7):587-588. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16791582\">[PubMed 16791582]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11470":"<p><b>Title</b> Ibrutinib / Clotrimazole (Oral)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: The management of this interaction differs when ibrutinib is used for the treatment of B-cell malignancies versus when ibrutinib is used for the treatment of graft versus host disease.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Clotrimazole (Oral) may increase the serum concentration of Ibrutinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> When ibrutinib is used for the treatment of B-cell malignancies, consider decreasing the ibrutinib dose to 140 mg daily when combined clotrimazole.<br><br>When ibrutinib is used for the treatment of graft versus host disease, no preemptive dose reduction is recommended when combined with clotrimazole. Patients should be monitored closely for ibrutinib toxicities and ibrutinib dose reductions should occur as needed based on adverse reactions.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 8 healthy volunteers, the pharmacokinetics of ibrutinib (560 mg single dose) were compared with the pharmacokinetics of ibrutinib (140 mg single dose) combined with the moderate CYP3A4 inhibitor grapefruit juice (240 mL single dose).<sup>1</sup> The dose-normalized ibrutinib maximum serum concentration (Cmax) and AUC increased 3.5-fold and 2.2-fold, respectively.<sup>1</sup> In a separate pharmacokinetic study described in the ibrutinib prescribing information, multiple doses of erythromycin (to achieve steady state) increased the ibrutinib Cmax and AUC 3.4-fold and 3-fold, respectively.<sup>2</sup><br><br>Ibrutinib prescribing information states that when ibrutinib is used for the treatment of B-cell malignancies, the ibrutinib dose should be decreased to 140 mg daily when combined with moderate CYP3A4 inhibitors.<sup>2</sup> When ibrutinib is used for the treatment of graft versus host disease, no preemptive dose reduction is recommended when combined with moderate CYP3A4 inhibitors, but patients should be monitored closely for ibrutinib toxicities and ibrutinib dose reductions should occur as needed based on adverse reactions.<sup>2</sup> Although ibrutinib product labeling lists cimetidine, ciprofloxacin, clotrimazole, cyclosporine, fluvoxamine, and tofisopam as examples of moderate CYP3A4 inhibitors,<sup>2</sup> the majority of clinical data suggests that these agents are more often classified as weak CYP3A4 inhibitors.<sup>3,4,5,6,7,8,9,10,11</sup><br><br>The mechanism of this interaction is likely due to inhibition of CYP3A4, an enzyme responsible for ibrutinib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. de Jong J, Skee D, Murphy J, et al. Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants. <i>Pharmacol Res Perspect</i>. 2015;3(4):e00156. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26171235\">[PubMed 26171235]</a></p>\n<p>2. Imbruvica (ibrutinib) [prescribing information]. Horsham, PA: Janssen Biotech Inc; August 2017.</p>\n<p>3. Martinez C, Albet C, Aqundez JA, et al. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. <i>Clin Pharmacol Ther</i>. 1999;65(4):369-376. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10223772\">[PubMed 10223772]</a></p>\n<p>4. Friedman H, Greenblatt DJ, Burstein ES, Scavone JM, Harmatz JS, Shader RI. Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. <i>J Clin Pharmacol</i>. 1988;28(3):228-233. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3360971\">[PubMed 3360971]</a></p>\n<p>5. Sriwiriyajan S, Samaeng M, Ridtitid W, Mahatthanatrakul W, Wongnawa M. Pharmacokinetic interactions between ciprofloxacin and itraconazole in healthy male volunteers. <i>Biopharm Drug Dispos</i>. 2011;32(3):168-174. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21360715\">[PubMed 21360715]</a></p>\n<p>6. Shahzadi A, Javed I, Aslam B, et al. Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers. <i>Pak J Pharm Sci</i>. 2011;24(1):63-68. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21190921\">[PubMed 21190921]</a></p>\n<p>7. Shord SS, Chan LN, Camp JR, et al. Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam. <i>Br J Clin Pharmacol</i>. 2010;69(2):160-166. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20233179\">[PubMed 20233179]</a></p>\n<p>8. Madsen JK, Jensen JD, Jensen LW, Pedersen EB. Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine. <i>Eur J Clin Pharmacol</i>. 1996;50(3):203-208. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8737760\">[PubMed 8737760]</a></p>\n<p>9. Lam YW, Alfaro CL, Ereshefsky L, Miller M. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. <i>J Clin Pharmacol</i>. 2003;43(11):1274-1282. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14551182\">[PubMed 14551182]</a></p>\n<p>10. Kashuba AD, Nafziger AN, Kearns GL, et al. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. <i>Clin Pharmacol Ther</i>. 1998;64(3):257-268. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9757149\">[PubMed 9757149]</a></p>\n<p>11. Drabant S, Toth M, Bereczki A, Bajnogel J, Tomlo J, Klebovich I. Effect of tofisopam on the single-oral-dose pharmacokinetics and pharmacodynamics of the cyp3a4 probe drug alprazolam. <i>Eur J Clin Pharmacol</i>. 2006;62(7):587-588. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16791582\">[PubMed 16791582]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11471":"<p><b>Title</b> Digoxin / Glecaprevir and Pibrentasvir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Glecaprevir and Pibrentasvir may increase the serum concentration of Digoxin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Measure serum digoxin concentrations before initiating glecaprevir/pibrentasvir. Reduce digoxin concentrations by decreasing the digoxin dose by approximately 50% or by modifying the dosing frequency; continue monitoring during concomitant therapy.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 healthy volunteers described in the prescribing information, glecaprevir/pibrentasvir (400 mg/120 mg once daily) increased the digoxin (0.5 mg single dose) maximum serum concentration and AUC 72% and 48%, respectively.<sup>1</sup><br><br>The glecaprevir/pibrentasvir prescribing information recommends to reduce the digoxin dose by approximately 50% or to modify the digoxin dosing interval when initiating glecaprevir/pibrentasvir.<sup>1</sup> Digoxin concentrations should continue to be monitored during therapy with glecaprevir/pibrentasvir.<sup>1</sup><br><br>The mechanism of this interaction is likely glecaprevir/pibrentasvir-mediated inhibition of P-glycoprotein, a transporter responsible for digoxin disposition.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mavyret (glecaprevir and pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc; August 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11472":"<p><b>Title</b> Glecaprevir and Pibrentasvir / Ethinyl Estradiol</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ethinyl Estradiol may enhance the adverse/toxic effect of Glecaprevir and Pibrentasvir. Specifically, the risk for ALT elevation may be increased with this combination. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concomitant use of glecaprevir/pibrentasvir and ethinyl estradiol is not recommended.</p> \n<p><b>Discussion</b> In pharmacokinetic studies of healthy volunteers (N = 11 to 12) described in the prescribing information, glecaprevir/pibrentasvir (300 mg/120 mg once daily) increased the ethinyl estradiol (20 to 35 mcg once daily) AUC 28% to 40% and maximum serum concentration 30% to 31%.<sup>1</sup><br><br>The glecaprevir/pibrentasvir prescribing information states that although the increases in ethinyl estradiol exposure are minimal, the combination of glecaprevir/pibrentasvir and ethinyl estradiol may still result in significant elevations in ALT and concomitant use is not recommended.<sup>1</sup><br><br>The mechanism of this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mavyret (glecaprevir and pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc; August 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11473":"<p><b>Title</b> Glecaprevir and Pibrentasvir / Atazanavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Atazanavir may increase the serum concentration of Glecaprevir and Pibrentasvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of glecaprevir/pibrentasvir and atazanavir. This combination is listed as contraindicated in the glecaprevir/pibrentasvir prescribing information.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 healthy volunteers described in the prescribing information, coadministration of atazanavir/ritonavir (300 mg/100 mg daily) and glecaprevir/pibrentasvir (300 mg/120 mg single dose) increased the glecaprevir AUC and maximum serum concentration (Cmax) more than 6.5-fold and 4.1-fold, respectively.<sup>1</sup> The AUC and Cmax of pibrentasvir increased more than 1.6-fold and 1.3-fold, respectively.<sup>1</sup><br><br>The glecaprevir/pibrentasvir prescribing information states that because atazanavir can significantly increase glecaprevir and pibrentasvir exposure, it may increase the risk for elevated ALT concentrations.<sup>1</sup> Use of glecaprevir/pibrentasvir with atazanavir is contraindicated.<sup>1</sup><br><br>The mechanism of this interaction has not been fully investigated but atazanavir-mediated inhibition of CYP3A4, BCRP, and SLCO1B1 (OATP1B1), enzymes and transporters responsible for glecaprevir/pibrentasvir metabolism and disposition, likely contributes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mavyret (glecaprevir and pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc; August 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11474":"<p><b>Title</b> Glecaprevir and Pibrentasvir / Lopinavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Lopinavir may increase the serum concentration of Glecaprevir and Pibrentasvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concomitant use of glecaprevir/pibrentasvir and lopinavir/ritonavir is not recommended.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 9 healthy volunteers described in the prescribing information, coadministration of lopinavir/ritonavir (400 mg/100 mg twice daily) and glecaprevir/pibrentasvir (300 mg/120 mg daily) increased the glecaprevir AUC and maximum serum concentration (Cmax) 4.4-fold and 2.6-fold, respectively.<sup>1</sup> The AUC and Cmax of pibrentasvir increased 2.5-fold and 1.4-fold, respectively.<sup>1</sup><br><br>The glecaprevir/pibrentasvir prescribing information states that because lopinavir/ritonavir can significantly increase glecaprevir and pibrentasvir exposure, it may increase the risk for toxicities.<sup>1</sup> Use of glecaprevir/pibrentasvir with lopinavir/ritonavir is not recommended.<sup>1</sup><br><br>The mechanism of this interaction has not been fully investigated but lopinavir-mediated inhibition of CYP3A4, BCRP, and SLCO1B1 (OATP1B1), enzymes and transporters responsible for glecaprevir/pibrentasvir metabolism and disposition, likely contributes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mavyret (glecaprevir and pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc; August 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11475":"<p><b>Title</b> Glecaprevir and Pibrentasvir / Darunavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Darunavir may increase the serum concentration of Glecaprevir and Pibrentasvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concomitant use of glecaprevir/pibrentasvir and darunavir is not recommended.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 8 healthy volunteers described in the prescribing information, coadministration of darunavir/ritonavir (800 mg/100 mg daily) and glecaprevir/pibrentasvir (300 mg/120 mg daily) increased the glecaprevir AUC and maximum serum concentration (Cmax) 5-fold and 3.1-fold, respectively.<sup>1</sup> The AUC and Cmax of pibrentasvir were unchanged, but the minimum serum concentration increased 1.7-fold.<sup>1</sup><br><br>The glecaprevir/pibrentasvir prescribing information states that because darunavir can significantly increase glecaprevir exposure, it may increase the risk for toxicities.<sup>1</sup> Use of glecaprevir/pibrentasvir with darunavir is not recommended.<sup>1</sup><br><br>The mechanism of this interaction has not been fully investigated but darunavir-mediated inhibition of CYP3A4, an enzyme responsible for glecaprevir metabolism, likely contributes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mavyret (glecaprevir and pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc; August 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11476":"<p><b>Title</b> AtorvaSTATin / Glecaprevir and Pibrentasvir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Glecaprevir and Pibrentasvir may increase the serum concentration of AtorvaSTATin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concomitant use of glecaprevir/pibrentasvir and atorvastatin is not recommended.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 11 healthy volunteers described in the prescribing information, glecaprevir/pibrentasvir (400 mg/120 mg once daily) increased the atorvastatin (10 mg daily) AUC and maximum serum concentration 8.3-fold and 22-fold, respectively.<sup>1</sup><br><br>The glecaprevir/pibrentasvir prescribing information states that because glecaprevir/pibrentasvir can increase atorvastatin concentrations and increase the risk of myopathy and rhabdomyolysis, concomitant use of glecaprevir/pibrentasvir and atorvastatin is not recommended.<sup>1</sup><br><br>The mechanism of this interaction has not been fully investigated, but glecaprevir/pibrentasvir-mediated inhibition of SLCO1B1/1B3 (OATP1B1/1B3), a transporter responsible for atorvastatin hepatic uptake, is likely primarily responsible. Glecaprevir/pibrentasvir-mediated weak inhibition of CYP3A4, an enzyme responsible for atorvastatin metabolism, may also contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mavyret (glecaprevir and pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc; August 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11477":"<p><b>Title</b> Simvastatin / Glecaprevir and Pibrentasvir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Glecaprevir and Pibrentasvir may increase the serum concentration of Simvastatin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concomitant use of glecaprevir/pibrentasvir and simvastatin is not recommended.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 healthy volunteers described in the prescribing information, glecaprevir/pibrentasvir (300 mg/120 mg once daily) increased the simvastatin (5 mg daily) AUC and maximum serum concentration (Cmax) 2.3-fold and 2-fold, respectively.<sup>1</sup> The AUC and Cmax of simvastatin acid increased 4.5-fold and 10.7-fold, respectively.<sup>1</sup><br><br>The glecaprevir/pibrentasvir prescribing information states that because glecaprevir/pibrentasvir can increase simvastatin concentrations and increase the risk of myopathy and rhabdomyolysis, concomitant use of glecaprevir/pibrentasvir and simvastatin is not recommended.<sup>1</sup><br><br>The mechanism of this interaction has not been fully investigated, but glecaprevir/pibrentasvir-mediated inhibition of SLCO1B1/1B3 (OATP1B1/1B3), a transporter responsible for simvastatin hepatic uptake, is likely primarily responsible. Glecaprevir/pibrentasvir-mediated weak inhibition of CYP3A4, an enzyme responsible for simvastatin metabolism, may also contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mavyret (glecaprevir and pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc; August 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11478":"<p><b>Title</b> Lovastatin / Glecaprevir and Pibrentasvir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Glecaprevir and Pibrentasvir may increase the serum concentration of Lovastatin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concomitant use of glecaprevir/pibrentasvir and lovastatin is not recommended.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 healthy volunteers described in the prescribing information, glecaprevir/pibrentasvir (300 mg/120 mg once daily) increased the lovastatin (10 mg daily) AUC 1.7-fold.<sup>1</sup> The AUC and maximum serum concentration of lovastatin acid increased 4.1-fold and 5.7-fold, respectively.<sup>1</sup><br><br>The glecaprevir/pibrentasvir prescribing information states that because glecaprevir/pibrentasvir can increase lovastatin concentrations and increase the risk of myopathy and rhabdomyolysis, concomitant use of glecaprevir/pibrentasvir and lovastatin is not recommended.<sup>1</sup><br><br>The mechanism of this interaction has not been fully investigated, but glecaprevir/pibrentasvir-mediated inhibition of SLCO1B1/1B3 (OATP1B1/1B3), a transporter responsible for lovastatin hepatic uptake, is likely primarily responsible. Glecaprevir/pibrentasvir-mediated weak inhibition of CYP3A4, an enzyme responsible for lovastatin metabolism, may also contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mavyret (glecaprevir and pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc; August 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11479":"<p><b>Title</b> HMG-CoA Reductase Inhibitors (Statins) / Glecaprevir and Pibrentasvir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Glecaprevir and Pibrentasvir may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use the lowest statin dose possible if combined with glecaprevir/pibrentasvir and monitor patients for increased statin effects/toxicities (eg, myopathy, rhabdomyolysis). Avoid concomitant use of glecaprevir/pibrentasvir with atorvastatin, lovastatin, or simvastatin. Limit rosuvastatin doses to 10 mg daily and reduce pravastatin doses by 50% upon initiation of glecaprevir/pibrentasvir.</p>\n<div>\n <p><b>HMG-CoA Reductase Inhibitors (Statins) Interacting Members</b> AtorvaSTATin, Fluvastatin, Lovastatin, Pitavastatin, Pravastatin, Red Yeast Rice, Rosuvastatin, Simvastatin</p>\n</div> \n<p><b>Discussion</b> In several pharmacokinetic studies (N = 11 to 12) described in the prescribing information, glecaprevir/pibrentasvir (300 mg to 400 mg/120 mg daily) increased the AUC of atorvastatin (8.3-fold), simvastatin (2.3-fold), simvastatin acid (4.5-fold), lovastatin (1.7-fold), lovastatin acid (4.1-fold), pravastatin (2.3-fold), and rosuvastatin (2.2-fold).<sup>1</sup><br><br>The glecaprevir/pibrentasvir prescribing information states that glecaprevir/pibrentasvir can increase statin concentrations and increase the risk of myopathy and rhabdomyolysis.<sup>1</sup> Avoid concomitant use of glecaprevir/pibrentasvir with atorvastatin, lovastatin, or simvastatin. Limit rosuvastatin doses to 10 mg daily and reduce pravastatin doses by 50% upon initiation of glecaprevir/pibrentasvir.<sup>1</sup> Use the lowest fluvastatin or pitavastatin dose possible.<sup>1</sup><br><br>The mechanism of this interaction has not been fully investigated, but glecaprevir/pibrentasvir-mediated inhibition of SLCO1B1/1B3 (OATP1B1/1B3), a transporter responsible for statin hepatic uptake, is likely primarily responsible. Glecaprevir/pibrentasvir-mediated weak inhibition of CYP3A4, an enzyme responsible for atorvastatin, simvastatin, and lovastatin metabolism, may also contribute. Glecaprevir/pibrentasvir-mediated inhibition of BCRP, a transporter responsible for rosuvastatin disposition may also play a role.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mavyret (glecaprevir and pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc; August 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11480":"<p><b>Title</b> Glecaprevir and Pibrentasvir / CycloSPORINE (Systemic)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: This interaction only applies to cyclosporine doses greater than 100 mg per day.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may increase the serum concentration of Glecaprevir and Pibrentasvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Glecaprevir/pibrentasvir is not recommended for use in patients requiring stable doses of cyclosporine greater than 100 mg per day.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 11 healthy volunteers described in the prescribing information, cyclosporine (400 mg single dose) coadministered with glecaprevir/pibrentasvir (300 mg/120 mg single dose) increased the glecaprevir AUC and maximum serum concentration (Cmax) 5.1-fold and 4.5-fold, respectively.<sup>1</sup> The pibrentasvir AUC increased 1.9-fold.<sup>1</sup> In separate pharmacokinetic study of 12 healthy volunteers, cyclosporine (100 mg single dose) only increased the glecaprevir AUC and Cmax 1.4-fold and 1.3-fold, respectively, and the AUC and Cmax of pibrentasvir were unchanged.<sup>1</sup><br><br>The glecaprevir/pibrentasvir prescribing information states that because higher doses of cyclosporine can increase glecaprevir and pibrentasvir concentrations and may increase the risk for adverse effects, glecaprevir/pibrentasvir is not recommended to be used in patients who require stable doses of cyclosporine of more than 100 mg per day.<sup>1</sup><br><br>The mechanism of this interaction has not been fully investigated, but cyclosporine-mediated inhibition of SLCO1B1 (OATP1B1) or BCRP, transporters responsible for glecaprevir/pibrentasvir hepatic uptake and disposition, is likely responsible. Cyclosporine-mediated inhibition of CYP3A4, an enzyme responsible for glecaprevir metabolism, may also contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mavyret (glecaprevir and pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc; August 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11481":"<p><b>Title</b> Glecaprevir and Pibrentasvir / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Glecaprevir and Pibrentasvir. RifAMPin may increase the serum concentration of Glecaprevir and Pibrentasvir. Specifically, a single dose of rifampin may increase glecaprevir/pibrentasvir concentrations, while chronic daily use of rifampin may decrease glecaprevir/pibrentasvir concentrations. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of glecaprevir/pibrentasvir and rifampin. This combination is listed as contraindicated in the glecaprevir/pibrentasvir prescribing information.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 healthy volunteers described in the prescribing information, rifampin (600 mg single dose) coadministered with glecaprevir/pibrentasvir (300 mg/120 mg single dose) increased the glecaprevir AUC and maximum serum concentration (Cmax) 8.6-fold and 6.5-fold, respectively.<sup>1</sup> Daily dosing of rifampin (600 mg daily) combined with glecaprevir/pibrentasvir (300 mg/120 mg single dose) decreased the glecaprevir AUC and Cmax 88% and 86%, respectively, and decreased the pibrentasvir AUC and Cmax 87% and 83%, respectively.<sup>1</sup><br><br>The glecaprevir/pibrentasvir prescribing information states that because daily dosing of rifampin significantly reduces glecaprevir and pibrentasvir serum concentrations, it may result in a loss of therapeutic efficacy.<sup>1</sup> Concomitant use of rifampin and glecaprevir/pibrentasvir is contraindicated.<sup>1</sup><br><br>The mechanism by which rifampin decreases glecaprevir/pibrentasvir concentrations is likely due to rifampin-mediated induction of CYP3A4 and/or P-glycoprotein, an enzyme and transporter responsible for glecaprevir/pibrentasvir metabolism and disposition. Single dose rifampin inhibits SLCOs (OATPs), transporters responsible for the hepatic uptake of glecaprevir/pibrentasvir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mavyret (glecaprevir and pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc; August 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11482":"<p><b>Title</b> Glecaprevir and Pibrentasvir / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Glecaprevir and Pibrentasvir. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased glecaprevir/pibrentasvir effects if combined with strong CYP3A4 inducers. Consider avoiding concomitant use, if possible.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 10 healthy volunteers described in the prescribing information, coadministration of the strong CYP3A4 inducer carbamazepine (200 mg twice daily) and glecaprevir/pibrentasvir (300 mg /120 mg single dose) decreased the glecaprevir maximum serum concentration (Cmax) and AUC 67% and 66%, respectively.<sup>1</sup> The pibrentasvir Cmax and AUC decreased 50% and 51%, respectively.<sup>1</sup> In a separate study of 12 healthy volunteers, another strong CYP3A4 inducer rifampin (600 mg daily) decreased the glecaprevir Cmax and AUC 86% and 88%, respectively, and decreased the pibrentasvir Cmax and AUC 83% and 87%, respectively.<sup>1</sup> <br><br>The glecaprevir/pibrentasvir prescribing information states that due to risk of decreased plasma concentrations and reduced efficacy, concomitant use with rifampin is contraindicated and concomitant use with carbamazepine is not recommended.<sup>1</sup> Although the prescribing information provides no recommendation for use with other strong CYP3A4 inducers, monitoring for decreased efficacy or possible avoidance of glecaprevir/pibrentasvir with strong CYP3A4 inducers appears warranted.<br><br>The mechanisms of these interactions have not been fully investigated, but induction of CYP3A4 and P-glycoprotein, an enzyme and transporter involved in glecaprevir/pibrentasvir metabolism and disposition, likely contributes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mavyret (glecaprevir and pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc; August 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11483":"<p><b>Title</b> Glecaprevir and Pibrentasvir / CYP3A4 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may decrease the serum concentration of Glecaprevir and Pibrentasvir. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased glecaprevir/pibrentasvir effects if combined with moderate CYP3A4 inducers. Consider avoiding concomitant use if possible.</p>\n<div>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n</div> \n<p><b>Discussion</b> No studies have been conducted to evaluate the effect of moderate CYP3A4 inducers on the pharmacokinetics of glecaprevir/pibrentasvir. However, in a pharmacokinetic study of 10 healthy volunteers described in the prescribing information, coadministration of the strong CYP3A4 inducer carbamazepine (200 mg twice daily) and glecaprevir/pibrentasvir (300 mg /120 mg single dose) decreased the glecaprevir maximum serum concentration (Cmax) and AUC 67% and 66%, respectively.<sup>1</sup> The pibrentasvir Cmax and AUC decreased 50% and 51%, respectively.<sup>1</sup> In a separate study of 12 healthy volunteers, another strong CYP3A4 inducer rifampin (600 mg daily) decreased the glecaprevir Cmax and AUC 86% and 88%, respectively, and decreased the pibrentasvir Cmax and AUC 83% and 87%, respectively.<sup>1</sup> <br><br>The glecaprevir/pibrentasvir prescribing information states that concomitant use of the moderate CYP3A4 inducer efavirenz may significantly decrease plasma concentrations of glecaprevir and pibrentasvir leading to reduced efficacy, and that concomitant use is not recommended.<sup>1</sup> Although the prescribing information provides no recommendation for use with other moderate CYP3A4 inducers, monitoring for decreased efficacy or possible avoidance of glecaprevir/pibrentasvir with moderate CYP3A4 inducers appears warranted.<br><br>The mechanisms of these interactions have not been fully investigated, but induction of CYP3A4 and P-glycoprotein, an enzyme and transporter involved in glecaprevir/pibrentasvir metabolism and disposition, likely contributes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mavyret (glecaprevir and pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc; August 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11484":"<p><b>Title</b> Glecaprevir and Pibrentasvir / P-glycoprotein/ABCB1 Inducers</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Glecaprevir and Pibrentasvir. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased glecaprevir/pibrentasvir effects if combined with P-glycoprotein inducers. Consider avoiding concomitant use, if possible.</p>\n<div>\n <p><b>P-glycoprotein/ABCB1 Inducers Interacting Members</b> Apalutamide, Fosphenytoin, Phenytoin, RifAMPin, St John's Wort</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 10 healthy volunteers described in the prescribing information, coadministration of carbamazepine (200 mg twice daily) and glecaprevir/pibrentasvir (300 mg /120 mg single dose) decreased the glecaprevir maximum serum concentration (Cmax) and AUC 67% and 66%, respectively.<sup>1</sup> The pibrentasvir Cmax and AUC decreased 50% and 51%, respectively.<sup>1</sup> In a separate study of 12 healthy volunteers, rifampin (600 mg daily) decreased the glecaprevir Cmax and AUC 86% and 88%, respectively, and decreased the pibrentasvir Cmax and AUC 83% and 87%, respectively.<sup>1</sup> <br><br>The glecaprevir/pibrentasvir prescribing information states that due to risk of decreased plasma concentrations and reduced efficacy, concomitant use with rifampin is contraindicated and concomitant use with carbamazepine is not recommended.<sup>1</sup> Although they provide no recommendation for use with P-glycoprotein (P-gp) inducers, monitoring for decreased efficacy or possible avoidance of glecaprevir/pibrentasvir with P-gp inducers appears warranted.<br><br>The mechanisms of these interactions have not been fully investigated, but induction of CYP3A4 and P-gp, an enzyme and transporter involved in glecaprevir/pibrentasvir metabolism and disposition, likely contributes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mavyret (glecaprevir and pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc; August 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11485":"<p><b>Title</b> Glecaprevir and Pibrentasvir / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Glecaprevir and Pibrentasvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concomitant use of glecaprevir/pibrentasvir and carbamazepine is not recommended.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 10 healthy volunteers described in the prescribing information, coadministration of carbamazepine (200 mg twice daily) and glecaprevir/pibrentasvir (300 mg /120 mg single dose) decreased the glecaprevir maximum serum concentration (Cmax) and AUC 67% and 66% respectively.<sup>1</sup> The pibrentasvir Cmax and AUC decreased 50% and 51%, respectively.<sup>1</sup><br><br>The glecaprevir/pibrentasvir prescribing information states that because carbamazepine can significantly decrease plasma concentrations of glecaprevir and pibrentasvir leading to reduced efficacy, the concomitant use of these agents is not recommended.<sup>1</sup><br><br>The mechanism of this interaction has not been fully investigated, but carbamazepine-mediated induction of CYP3A4 likely contributes. Induction of other transporters involved in glecaprevir/pibrentasvir disposition (eg, P-glycoprotein, BCRP) may also play a role.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mavyret (glecaprevir and pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc; August 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11486":"<p><b>Title</b> Glecaprevir and Pibrentasvir / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Glecaprevir and Pibrentasvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concomitant use of glecaprevir/pibrentasvir and St John's wort is not recommended.</p> \n<p><b>Discussion</b> No studies have been conducted to evaluate the effect of St John's wort on the pharmacokinetics of glecaprevir/pibrentasvir. However, in a pharmacokinetic study of 10 healthy volunteers described in the prescribing information, coadministration of carbamazepine (200 mg twice daily) and glecaprevir/pibrentasvir (300 mg /120 mg single dose) decreased the glecaprevir maximum serum concentration (Cmax) and AUC 67% and 66%, respectively.<sup>1</sup> The pibrentasvir Cmax and AUC decreased 50% and 51%, respectively.<sup>1</sup> In a separate study of 12 healthy volunteers, rifampin (600 mg daily) decreased the glecaprevir Cmax and AUC 86% and 88%, respectively, and decreased the pibrentasvir Cmax and AUC 83% and 87%, respectively.<sup>1</sup> <br><br>The glecaprevir/pibrentasvir prescribing information states that because St John's wort may significantly decrease plasma concentrations of glecaprevir and pibrentasvir leading to reduced efficacy, the concomitant use of these agents is not recommended.<sup>1</sup><br><br>The mechanisms of these interaction have not been fully investigated, but induction of CYP3A4 and P-glycoprotein, an enzyme and transporter involved in glecaprevir/pibrentasvir metabolism and disposition, likely contributes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mavyret (glecaprevir and pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc; August 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11487":"<p><b>Title</b> Glecaprevir and Pibrentasvir / Efavirenz</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Efavirenz may decrease the serum concentration of Glecaprevir and Pibrentasvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concomitant use of glecaprevir/pibrentasvir and efavirenz is not recommended.</p> \n<p><b>Discussion</b> No studies have been conducted to evaluate the effect of efavirenz on the pharmacokinetics of glecaprevir/pibrentasvir. However, in a pharmacokinetic study of 10 healthy volunteers described in the prescribing information, coadministration of carbamazepine (200 mg twice daily) and glecaprevir/pibrentasvir (300 mg /120 mg single dose) decreased the glecaprevir maximum serum concentration (Cmax) and AUC 67% and 66%, respectively.<sup>1</sup> The pibrentasvir Cmax and AUC decreased 50% and 51%, respectively.<sup>1</sup> In a separate study of 12 healthy volunteers, rifampin (600 mg daily) decreased the glecaprevir Cmax and AUC 86% and 88%, respectively, and decreased the pibrentasvir Cmax and AUC 83% and 87%, respectively.<sup>1</sup> <br><br>The glecaprevir/pibrentasvir prescribing information states that because efavirenz may significantly decrease plasma concentrations of glecaprevir and pibrentasvir leading to reduced efficacy, the concomitant use of these agents is not recommended.<sup>1</sup><br><br>The mechanisms of these interaction have not been fully investigated, but induction of CYP3A4 and P-glycoprotein, an enzyme and transporter involved in glecaprevir/pibrentasvir metabolism and disposition, likely contributes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mavyret (glecaprevir and pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc; August 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11488":"<p><b>Title</b> Tacrolimus (Systemic) / Glecaprevir and Pibrentasvir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Glecaprevir and Pibrentasvir may increase the serum concentration of Tacrolimus (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased tacrolimus concentrations and effects if combined with glecaprevir/pibrentasvir. A tacrolimus dose reduction may be required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 10 healthy volunteers described in the prescribing information, glecaprevir/pibrentasvir (300 mg/120 mg daily) increased the tacrolimus (1 mg single dose) AUC and maximum serum concentration 45% and 50%, respectively.<sup>1</sup><br><br>The glecaprevir/pibrentasvir prescribing information states that no tacrolimus dose adjustment is required when combined with glecaprevir/pibrentasvir.<sup>1</sup> The tacrolimus prescribing information states that even weak CYP3A4 inhibitors (ie, glecaprevir/pibrentasvir) can increase tacrolimus concentrations and increase the risk of serious adverse reactions.<sup>2</sup> It is recommended to monitor tacrolimus concentrations closely and to decrease the tacrolimus dose if needed.<sup>2</sup><br><br>The mechanism of this interaction is likely glecaprevir/pibrentasvir-mediated inhibition of CYP3A4 and P-glycoprotein, an enzyme and transporter involved in tacrolimus metabolism and distribution.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mavyret (glecaprevir and pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc; August 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11489":"<p><b>Title</b> Glecaprevir and Pibrentasvir / Omeprazole</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Omeprazole may decrease the serum concentration of Glecaprevir and Pibrentasvir. Specifically, serum concentrations of glecaprevir may be reduced. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of healthy volunteers described in the prescribing information, coadministration of glecaprevir/pibrentasvir (300 mg/120 mg single dose) with omeprazole (20 mg daily) decreased the glecaprevir AUC and maximum serum concentration (Cmax) 29% and 22%, respectively, and decreased the omeprazole AUC and Cmax 21% and 43%, respectively.<sup>1</sup> In a separate pharmacokinetic study of healthy volunteers, omeprazole (40 mg daily) given 1 hour before glecaprevir/pibrentasvir (300 mg/120 mg single dose) decreased the glecaprevir AUC and Cmax 51% and 63%, respectively.<sup>1</sup> Pibrentasvir pharmacokinetic parameters were unchanged in both studies.<sup>1</sup><br><br>The glecaprevir/pibrentasvir prescribing information states that no dose adjustment, special caution, or increased monitoring is required when glecaprevir/pibrentasvir is combined with omeprazole.<sup>1</sup><br><br>The mechanism of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mavyret (glecaprevir and pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc; August 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11490":"<p><b>Title</b> Raltegravir / Glecaprevir and Pibrentasvir</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Glecaprevir and Pibrentasvir may increase the serum concentration of Raltegravir. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 healthy volunteers described in the prescribing information, glecaprevir/pibrentasvir (300 mg/120 mg daily) increased the raltegravir (400 mg twice daily) AUC, maximum serum concentration, and minimum serum concentration 1.5-fold, 1.3-fold, and 2.6-fold, respectively.<sup>1</sup><br><br>The mechanism of this interaction is likely glecaprevir/pibrentasvir-mediated inhibition of UGT1A1, an enzyme responsible for raltegravir metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mavyret (glecaprevir and pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc; August 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11491":"<p><b>Title</b> Glecaprevir and Pibrentasvir / Cobicistat</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cobicistat may increase the serum concentration of Glecaprevir and Pibrentasvir. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased glecaprevir/pibrentasvir effects/toxicities if combined with cobicistat or cobicistat-containing products.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 11 healthy volunteers described in the prescribing information, coadministration of glecaprevir/pibrentasvir (300 mg/120 mg daily) and elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (150 mg/150 mg/200 mg/10 mg once daily) increased the glecaprevir AUC and maximum serum concentration (Cmax) 3.1-fold and 2.5-fold, respectively.<sup>1</sup> The AUC of pibrentasvir increased 1.6-fold and the Cmax remained unchanged.<sup>1</sup><br><br>The glecaprevir/pibrentasvir prescribing information states that glecaprevir/pibrentasvir can be given with cobicistat and no dose adjustment is required.<sup>1</sup><br><br>The mechanism of this potential interaction is likely cobicistat-mediated inhibition of CYP3A4, BCRP, and SLCO1B1/1B3 (OATP1B1/1B3), an enzyme and transporters responsible for glecaprevir/pibrentasvir metabolism and disposition.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mavyret (glecaprevir and pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc; August 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11492":"<p><b>Title</b> PACLitaxel (Protein Bound) / Clopidogrel</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Clopidogrel may increase the serum concentration of PACLitaxel (Protein Bound). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor closely for evidence of severe neuropathy or neutropenia with use of this combination since the combination may be associated with an increased risk of these toxicities.</p> \n<p><b>Discussion</b> The risk for severe neuropathy among patients treated with high-dose paclitaxel was increased with concurrent clopidogrel (HR=2.3 (95% CI: 1.1 to 4.5)) according to an adjusted analysis of 48 cases (patients receiving the combination) and 88 matched controls (receiving paclitaxel and low-dose aspirin).<sup>1</sup> The risk among all paclitaxel-treated patients (ie, not restricted to higher doses) was non-significantly higher (HR=1.7 (0.9 to 3.0)). Servere peripheral neuropathy was observed in 22% of 9 patients receiving both paclitaxel and clopidogrel versus in 2% of 135 paclitaxel-treated controls (no clopidogrel) (OR=12) and in none of 17 patients receiving paclitaxel and aspirin.<sup>2</sup> It is important to note that the cases and controls were not well-matched in this study, with some clear differences between clopidogrel-treated and non-clopidogrel-treated patients. Another small study of 8 paclitaxel-treated patients reported both greater neutrophil reduction and lower total neutrophil counts with concurrent clopidogrel (5 of 8 patients were receiving clopidogrel).<sup>3</sup> A published case report also describes severe neuropathy leading to paclitaxel discontinuation after 4 treatment cycles in a 60-year-old women who was being treated with both paclitaxel and clopidogrel.<sup>4</sup><br><br>The suspected mechanism for this apparent interaction is inhibition of the CYP2C8-mediated paclitaxel metabolism by the acyl-beta-D-glucuronide metabolite of clopidogrel.<sup>1,4</sup> Consistent with this, an in vitro study reported a 51% to 77% reduction in paclitaxel alpha-hydroxylation in human liver microsomes with the addition of clopidogrel acyl-beta-D-glucuronide.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Agergaard K, Mau-Sorensen M, Stage TB, et al. Clopidogrel-paclitaxel drug-drug interaction: a pharmacoepidemiologic study. <i>Clin Pharmacol Ther</i>. 2017;102(3):547-553. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28224612\">[PubMed 28224612]</a></p>\n<p>2. Matsuo M, Ito H, Takemura Y, et al. Increased risk of paclitaxel-induced peripheral neuropathy in patients using clopidogrel: a retrospective pilot study. <i>J Anesth</i>. 2017;31(4):631-635. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28451807\">[PubMed 28451807]</a></p>\n<p>3. Shinoda Y, Kimura M, Usami E, Asano H, Yoshimura T. Potential drug interaction between paclitaxel and clopidogrel. <i>Biomed Rep</i>. 2016;5(1):141-145. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27347418\">[PubMed 27347418]</a></p>\n<p>4. Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K. Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60-year-old Caucasian woman with ovarian carcinoma. <i>Br J Clin Pharmacol</i>. 2016;81(2):313-315. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26446447\">[PubMed 26446447]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11493":"<p><b>Title</b> PACLitaxel (Conventional) / Clopidogrel</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Clopidogrel may increase the serum concentration of PACLitaxel (Conventional). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor closely for evidence of severe neuropathy or neutropenia with use of this combination since the combination may be associated with an increased risk of these toxicities.</p> \n<p><b>Discussion</b> The risk for severe neuropathy among patients treated with high-dose paclitaxel was increased with concurrent clopidogrel (HR=2.3 (95% CI: 1.1 to 4.5)) according to an adjusted analysis of 48 cases (patients receiving the combination) and 88 matched controls (receiving paclitaxel and low-dose aspirin).<sup>1</sup> The risk among all paclitaxel-treated patients (ie, not restricted to higher doses) was non-significantly higher (HR=1.7 (0.9 to 3.0)). Servere peripheral neuropathy was observed in 22% of 9 patients receiving both paclitaxel and clopidogrel versus in 2% of 135 paclitaxel-treated controls (no clopidogrel) (OR=12) and in none of 17 patients receiving paclitaxel and aspirin.<sup>2</sup> It is important to note that the cases and controls were not well-matched in this study, with some clear differences between clopidogrel-treated and non-clopidogrel-treated patients. Another small study of 8 paclitaxel-treated patients reported both greater neutrophil reduction and lower total neutrophil counts with concurrent clopidogrel (5 of 8 patients were receiving clopidogrel).<sup>3</sup> A published case report also describes severe neuropathy leading to paclitaxel discontinuation after 4 treatment cycles in a 60-year-old women who was being treated with both paclitaxel and clopidogrel.<sup>4</sup><br><br>The suspected mechanism for this apparent interaction is inhibition of the CYP2C8-mediated paclitaxel metabolism by the acyl-beta-D-glucuronide metabolite of clopidogrel.<sup>1,4</sup> Consistent with this, an in vitro study reported a 51% to 77% reduction in paclitaxel alpha-hydroxylation in human liver microsomes with the addition of clopidogrel acyl-beta-D-glucuronide.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Agergaard K, Mau-Sorensen M, Stage TB, et al. Clopidogrel-paclitaxel drug-drug interaction: a pharmacoepidemiologic study. <i>Clin Pharmacol Ther</i>. 2017;102(3):547-553. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28224612\">[PubMed 28224612]</a></p>\n<p>2. Matsuo M, Ito H, Takemura Y, et al. Increased risk of paclitaxel-induced peripheral neuropathy in patients using clopidogrel: a retrospective pilot study. <i>J Anesth</i>. 2017;31(4):631-635. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28451807\">[PubMed 28451807]</a></p>\n<p>3. Shinoda Y, Kimura M, Usami E, Asano H, Yoshimura T. Potential drug interaction between paclitaxel and clopidogrel. <i>Biomed Rep</i>. 2016;5(1):141-145. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27347418\">[PubMed 27347418]</a></p>\n<p>4. Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K. Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60-year-old Caucasian woman with ovarian carcinoma. <i>Br J Clin Pharmacol</i>. 2016;81(2):313-315. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26446447\">[PubMed 26446447]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11494":"<p><b>Title</b> Lanthanum / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may diminish the therapeutic effect of Lanthanum. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Administer antacid products at least two hours before or after lanthanum.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> The patient counseling section of the lanthanum prescribing information recommends administration of antacid products at least two hours before or two hours after lanthanum administration, but this interaction warning is not present in other sections of the labeling (though there is a warning about potential interactions with drugs that interact with antacids).<sup>1</sup><br><br>The mechanism for any possible interaction is not known. It is unclear if antacid components may bind with lanthanum or if there is another suspected mechanism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Fosrenol (lanthanum) [prescribing information]. Lexington, MA: Shire US Inc.; February 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11495":"<p><b>Title</b> QTc-Prolonging Agents (Highest Risk) / Amifampridine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Amifampridine may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of amifampridine with drugs that are known to prolong the QT interval is contraindicated.</p>\n<div>\n <p><b>QTc-Prolonging Agents (Highest Risk) Interacting Members</b> Ajmaline, Amiodarone, Anagrelide, Arsenic Trioxide, Artemether, Asenapine, Astemizole, Bepridil, Cisapride, Citalopram, Deutetrabenazine, Disopyramide, Dofetilide, Domperidone, Dosulepin, Dronedarone, Eliglustat, FLUoxetine, Flupentixol, Halofantrine, Ibutilide, Iloperidone, Lopinavir, Lumefantrine, MiFEPRIStone, Nilotinib, Paliperidone, Pimavanserin, Pimozide, Pipamperone [INT], Procainamide, QUEtiapine, QuiNIDine, QuiNINE, Radotinib, Ribociclib, Sotalol, Sparfloxacin, Sulpiride, Terfenadine, Tetrabenazine, Thioridazine, Toremifene, Vandetanib, Vemurafenib, Vernakalant, Ziprasidone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Amifampridine product labeling states that use with known QT-prolonging drugs is contraindicated.<sup>1</sup> A study cited in the labeling found no significant effect of amifampridine on the QT interval following administration of single doses (30 mg or 60 mg) to 52 healthy volunteers who were slow acetylators (ie, expected to have higher concentrations of amifampridine).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Firdapse (amifampridine) [summary of product characteristics]. London, United Kingdom: BioMarin Europe Limited; June 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11496":"<p><b>Title</b> RifAMPin / Amifampridine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Amifampridine may enhance the QTc-prolonging effect of RifAMPin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of amifampridine with drugs that are known to prolong the QT interval is contraindicated.</p> \n<p><b>Discussion</b> Amifampridine product labeling states that use with known QT-prolonging drugs is contraindicated.<sup>1</sup> A study cited in the labeling found no significant effect of amifampridine on the QT interval following administration of single doses (30 mg or 60 mg) to 52 healthy volunteers who were slow acetylators (ie, expected to have higher concentrations of amifampridine).<br><br>Rifampin is specifically listed in this labeling as a drug that prolongs the QT interval, but the rationale for this warning is unclear as rifampin is not a known QT-prolonging drug.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Firdapse (amifampridine) [summary of product characteristics]. London, United Kingdom: BioMarin Europe Limited; June 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11497":"<p><b>Title</b> Amifampridine / Ketoconazole (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ketoconazole (Systemic) may enhance the QTc-prolonging effect of Amifampridine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of amifampridine with drugs that are known to prolong the QT interval is contraindicated. The amifampridine labeling lists ketoconazole as an example of such drugs despite unclear evidence supporting ketoconazole as a QT-prolonging drug.</p> \n<p><b>Discussion</b> Amifampridine product labeling states that use with known QT-prolonging drugs is contraindicated.<sup>1</sup> A study cited in the labeling found no significant effect of amifampridine on the QT interval following administration of single doses (30 mg or 60 mg) to 52 healthy volunteers who were slow acetylators (ie, expected to have higher concentrations of amifampridine.<br><br>Ketoconazole is specifically listed in this labeling as a drug that prolongs the QT interval, but the rationale for this warning is unclear as ketoconazole is not a known QT-prolonging drug. Most reports of ketoconazole-associated QT prolongation involve ketoconazole increasing the concentration of another drug that can prolong the QT interval, reflecting a drug metabolism interaction and not a QT effect. A published case report does describe QT prolongation that was attributed to ketoconazole itself (ie, not due to a metabolism-related interaction).<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Firdapse (amifampridine) [summary of product characteristics]. London, United Kingdom: BioMarin Europe Limited; June 2017.</p>\n<p>2. Mok NS, Lo YK, Tsui PT, Lam CW. Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug. <i>J Cardiovasc Electrophysiol</i>. 2005;16(12):1375-1377. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16403073\">[PubMed 16403073]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11498":"<p><b>Title</b> Anticholinergic Agents / Amifampridine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Amifampridine may diminish the anticholinergic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Amifampridine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for evidence of decreased amifampridine effects with use of this combination.</p>\n<div>\n <p><b>Anticholinergic Agents Interacting Members</b> Aclidinium, Acrivastine, Amitriptyline, Amoxapine, Atropine (Ophthalmic), Atropine (Systemic), Belladonna, Benperidol, Benztropine, Bilastine, Biperiden, Bromperidol, Brompheniramine, Buclizine, Carbinoxamine, Cetirizine (Systemic), Chlorpheniramine, ChlorproMAZINE, Cimetropium, Clemastine, Clidinium, ClomiPRAMINE, CloZAPine, Cyclizine, Cyclobenzaprine, Cyclopentolate, Cyproheptadine, Darifenacin, Desipramine, Dexbrompheniramine, Dexchlorpheniramine, Dicyclomine, DimenhyDRINATE, DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Disopyramide, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Fesoterodine, Fexofenadine, FlavoxATE, Flupentixol, FluPHENAZine, Glycopyrrolate (Oral Inhalation), Glycopyrrolate (Systemic), Haloperidol, Homatropine, HydrOXYzine, Hyoscyamine, Imidafenacin, Imipramine, Ipratropium (Nasal), Ipratropium (Oral Inhalation), Isocarboxazid, Ketotifen (Systemic), Levocetirizine, Lofepramine, Loratadine, Loxapine, Maprotiline, Meclizine, Melitracen [INT], Mepenzolate, Mequitazine, Methotrimeprazine, Methscopolamine, Methylene Blue, Moclobemide, Molindone, Nefopam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Orphenadrine, Oxatomide, Oxomemazine, Oxybutynin, Periciazine, Perphenazine, Phenelzine, Pheniramine, Phenyltoloxamine, Pimozide, Pizotifen, Prifinium, Prochlorperazine, Procyclidine, Promazine, Promethazine, Propantheline, Propiverine, Protriptyline, Pyrilamine (Systemic), QUEtiapine, QuiNIDine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Solifenacin, Syrian Rue, Thioridazine, Thiothixene, Thonzylamine, Tiotropium, Tiropramide, Tolterodine, Tranylcypromine, Trifluoperazine, Trihexyphenidyl, Trimeprazine, Trimethobenzamide, Trimipramine, Triprolidine, Trospium, Umeclidinium, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Amifampridine product labeling states that use with drugs that have known anticholinergic effects may result in decreased effects of amifampridine.<sup>1</sup> The anticholinergic effects of the anticholinergic drug may also be diminished. Amifampridine is thought to facilitate the release of acetylcholine from nerve endings via enhanced transport of calcium into the nerve terminals.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Firdapse (amifampridine) [summary of product characteristics]. London, United Kingdom: BioMarin Europe Limited; June 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11499":"<p><b>Title</b> Amifampridine / Acetylcholinesterase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Amifampridine. Amifampridine side effects may also be increased. Amifampridine may enhance the therapeutic effect of Acetylcholinesterase Inhibitors. Acetylcholinesterase inhibitor side effects may also be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of increased effects of both amifampridine and the acetylcholinesterase inhibitor.</p>\n<div>\n <p><b>Acetylcholinesterase Inhibitors Interacting Members</b> Distigmine, Donepezil, Edrophonium, Galantamine, Neostigmine, Physostigmine, Pyridostigmine, Rivastigmine</p>\n</div> \n<p><b>Discussion</b> Amifampridine product labeling states that use with drugs that have known cholinergic effects, such as acetylcholinesterase inhibitors, may result in increased effects of both amifampridine and the cholinergic agent.<sup>1</sup> Amifampridine is thought to facilitate the release of acetylcholine from nerve endings via enhanced transport of calcium into the nerve terminals.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Firdapse (amifampridine) [summary of product characteristics]. London, United Kingdom: BioMarin Europe Limited; June 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}